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Abstract 
The application of heat to treat disease can be dated back over 5000 years. Ancient 
Egyptian papyrus records describe heated instruments being used to cauterise breast 
tumours. In recent times, hyperthermia range temperatures are increasingly routinely used 
to treat cancer. Heating tumours alongside conventional therapies and pre-heating aqueous 
drug suspensions prior to administration are both commonplace in oncology clinics. Despite 
this, the mechanisms which underpin the efficacy of hyperthermia therapy in cancer 
treatment remain poorly understood. In particular, the impact of temperature on cancer cell 
cycle dynamics is under explored. We set out to investigate these mechanisms. We 
employed time lapse confocal microscopy and fluorescence ubiquitin-based cell cycle 
indicator expressing cancer cell lines to interrogate the effects of temperature on the cell 
cycle. To complement our investigation, we utilised the open source cancer genomics 
platforms cBioPortal and XenaBrowser to explore potential molecular determinants of cancer 
thermosensitivity. Through tracking the breast cancer cell line MCF-7 we observed 
hyperthermia to result in increased instances of endoreplication and mitotic catastrophe 
induced cell death. We also highlight components of the T complex protein ring complex as 
playing a potential role in testicular cancer. These findings will guide design of future cancer 
thermosensitivity study and may contribute towards novel adjuvant therapeutic cancer 
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1. Introduction  
1.1. Cancer as a disease  
1.1.1. The burden of cancer 
Cancer is the second leading cause of death globally with an estimated 9.6 million deaths 
worldwide in 2018 (Ferlay et al., 2019). The high mortality rate, significant morbidity, and 
complexities involved in the treatment of cancer carry with it an economic burden of £7.6 billion 
per year in the UK alone (Smith, 2020). These statistics emphasise the need for advancement 
in our understanding of cancer in order to aid in the development of novel therapeutic avenues 
to alleviate the diseases economic burden and impact on public health.    
1.1.2. The biology of cancer  
The developed human body consists of approximately 3.72 × 1013 cells (Bianconi et al., 2013). 
The vast majority reside either terminally differentiated, or in a dormant state known as 
quiescence (Potten and Loeffler, 1990). Many cells, however, divide and differentiate in order 
to facilitate growth and maintain life (Kaneko and Yomo, 1994). Evolution has led to the 
development of complex multi-layered biochemical signalling networks which transmit 
information within and between cells in order to regulate a proper balance of proliferation, 
differentiation, quiescence, and programmed cell death (Sever and Brugge, 2015). It is a 
dysregulation of these processes which leads to cancer. An imbalance in the complex network 
of growth and death signals promotes aberrant proliferation. After multiple generations these 
cells present as a neoplasm; literally a new growth (Hanahan and Weinberg, 2011). Almost 
every cell type in the body has the capacity to dysregulate cell cycling in this way. Thus, cancer 
shouldn’t be thought of as an individual disease, but rather a family of diseases (Hoadley et 
al., 2018). To add further complexity, the major genes responsible for oncogenesis, tumour 
suppressor genes and proto-oncogenes, often differ in their mutational profile between 
individuals (Muir and Nunney, 2015). This variability in genetic signature can result in vastly 
different phenotypic profiles between patients whose cancers share the same tissue of origin. 
This inter-individual heterogeneity leads to complications in designing therapeutic regimens 
(Kittaneh et al., 2013).  
 
Cells usually proliferate in a highly regulated manner, progressing through defined phases 
collectively known as the cell cycle (Vermeulen et al., 2003). A disruption in cell cycle 
regulation can lead to reduced DNA replication fidelity, promoting genomic instability and thus 
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increasing mutational burden promoting neoplasms to select for new characteristics (Hanahan 
and Weinberg, 2011). Just as Darwinian evolution dictates for the selection of randomly 
occurring mutations which confer organismal fitness, cancerous cells select for mutations 
which confer fitness at the cellular level, promoting proliferation and survival (Little, 2010). For 
example, once a tumour outgrows its local microenvironment, selection pressure is placed on 
cells to acquire the capability to break through extracellular matrices and travel through blood 
and lymphatic vessels in order to inhabit new compartments within the body (Seyfried and 
Huysentruyt, 2013). This process, known as metastasis, is strongly correlated with poor 
prognosis due to pathophysiological accumulation of neoplastic cells in multiple sites and 
subsequent complexities involved in treatment (Riihimäki et al., 2013). Furthermore, the 
interaction between non-neoplastic cells and cancer cells within the tumour microenvironment 
play an important role in cancer pathogenesis. For example, it is widely accepted that tumour-
associated-macrophages are obligate partners for tumour invasion and metastasis (Condeelis 
and Pollard, 2006). It is evident that oncogenesis is a complex process involving multiple 
dysregulated molecular and cellular components; at the centre of the disease however, is 
aberrant cell cycle regulation (Knox, 2010). 
1.2. Cancer and the cell cycle 
1.2.1. Cell cycle phases 
The cell cycle is primarily characterised by four consecutive phases. In the first phase, G1, 
cells undergo increased growth and synthesize the components needed for DNA replication 
(Donjerkovic and Scott, 2000). Following G1 cells enter S phase, otherwise known as 
synthesis phase, where DNA and chromosomes undergo duplication (Bertoli et al., 2013). 
Subsequently, a further growth phase coined G2 commences where the cell increases protein 
synthesis in order to generate the machinery needed for the next phase, mitosis, where the 
cell divides (see figure 1.1)(Murray, 1993). The phases either side of M phase, where most 
cells generally reside, are collectively known as interphase (Vorsanova et al., 2010). Cells 
have evolved a multitude of mechanisms to drive cycling through these defined phases in a 
highly regulated manner. Signalling networks regulate the cycle ensuring phase directionality 
and provide checkpoints that act as a surveillance system to monitor the integrity and fidelity 
of cell cycle events. In cancer these mechanisms go awry, checkpoints become ignored, and 




Figure 1. Cell cycle phases. Dividing cells pass through consecutive phases collectively 
known as the cell cycle. Growth 1 (G1) cells undergo metabolic changes in order prepare the 
cell for DNA synthesis. Synthesis phase (S) refers to the stage in which the cell replicates its 
chromosomes in preparation for providing progeny with equal genomic material. Growth 2 
(G2) phase represents further growth and massive upregulation of protein synthesis in order 
to generate the machinery needed for cell division. Mitosis (M) the cell segregates its 
chromosomes and divides (Bartee et al., 2017). 
1.2.2. DNA damage response checkpoints 
It is estimated that the human body suffers tens of thousands of DNA lesions per day (Lindahl 
and Barnes, 2000). This damage, if not repaired, or repaired incorrectly, can lead to cell 
heritable mutations which can disrupt cell cycle regulation and promote tumorigenesis. Some 
lesions arise through physiological processes such as DNA replication base-pair mismatching, 
and others due to exposure of exogenous toxic substances such as those found in tobacco 
smoke (Furrukh, 2013; Umar and Kunkel, 1997). To combat these degenerative changes, 
cells have evolved surveillance mechanisms which scan the genome and halt the cell cycle in 
order facilitate the repair of damage or signal for the destruction of the cell (Zhou and Elledge, 
2000). These mechanisms act to avoid producing progeny with aberrant genetic lesions which 
may promote dysregulated cycling. 
 
These processes are collectively known as the DNA damage response (DDR). The DDR is 
active throughout the entirety of the cell cycle and may alter the cycle at any given phase. 
Individual checkpoints are generally defined by the phase in which is the cell stalled (Houtgraaf 
et al., 2006). Although distinct molecular pathways have been demonstrated to act at specific 
phases, DDR proteins are often shared between phase checkpoints (Zhou and Elledge, 2000). 
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The response can be thought of as consisting of three core components; damage sensors 
and signal transducers, mediators, and effectors. Sensors act to initiate the signalling 
response to incorrect DNA structures (McGowan and Russell, 2004). The best understood of 
these is proliferating cell nuclear antigen (PCNA). PCNA is an essential processing factor in 
DNA replication and acts as a scaffold for the recruitment of factors needed for base mismatch 
repair (Umar et al., 1996; Majka and Burgers, 2004). Two master DDR signal transducers are 
the conserved and related serine/threonine kinases ataxia-telangiectasia mutated (ATM) and  
ataxia telangiectasia and Rad3-related protein (ATR). Following DNA damage hundreds of 
proteins are phosphorylated in an ATM or ATR dependent manner (Bensimon et al., 2010). 
ATM is activated predominantly by DNA double-strand breaks and ATR more generally in 
response to DNA damage (Maréchal and Zou, 2013). Inherited dysfunctional ATM is 
responsible for the neurodegenerative syndrome ataxia telangiectasia, which not surprisingly 
predisposes individuals to a range of cancers (Savitsky et al., 1995). Although there are 
distinct substrates between the two, there is also a considerable overlap. An important 
overlapping substrate is the tumour suppressor p53, often referred to as the guardian of the 
genome (Kim et al., 1999; Toufektchan and Toledo, 2018).  
 
Checkpoint kinase 1 (CHK1) and checkpoint kinase 2 (CHK2), also serine/threonine kinases, 
act as DDR effectors, phosphorylating downstream targets and halting the cell cycle. In 
mammals, CHK1 and CHK2 play an important role in all checkpoint DDR signalling pathways. 
RAD53 and CDS1, CHK2 yeast homologs, respond to replication blocks and DNA damage, 
whereas yeast CHK1 seems to act only in cell cycle arrest in response to damage (Brown et 
al., 1999; Matsuoka et al., 1998). CHK1 and CHK2 are activated via phosphorylation and 
transduced interchangeably by ATM or ATR depending on the specific damage scenario (Liu 
et al., 2000,p.1; Melchionna et al., 2000). These proteins then go onto mediate cell cycle arrest 
through phosphorylation and inactivation of proteins involved in driving the cell cycle. 
 
Specific DDR signalling generally depends of the type of DNA damage (Jackson and Bartek, 
2009). The G1/S checkpoint can be mediated through the phosphorylation and deactivation 
of dual specificity phosphatase cell division cycle protein 25A (CDC25A) by CHK1 or CHK2. 
CDC25A promotes entry past the G1/S transition through the desphosphorylation and 
activation of cyclin dependent kinase 2 (CDK2)(Hoffmann et al., 1994). Two well understood 
pathways are known to regulate an intra-S-phase checkpoint. The first, mediated by ATM and 
ATR, is similar to the G1/S checkpoint, arresting cycle progression through CDC25A 
inactivation (Sørensen et al., 2003, p.1). The second involves NBS1, the culprit responsible 
for the chromosomal instability disorder Nijmen Breakage syndrome (NBS) which predisposes 
individuals to a plethora of cancers. NBS1 in complex with p95 binds to hRAD50 and hMRE11 
 5 
following their recognition of DNA double strand breakages and signals for p53 dependent 
cycle arrest (Jongmans et al., 1997). The G2/M checkpoint prevents the cell from entering 
mitosis. As is the case with previous checkpoints, the specific DNA lesion dictates the 
signalling pathway activated. ATM/ATR-CHK1/2-CDC25 pathways previously described are 
activated in response to double strand breaks and lesions which arise from UV damage 
(Matsuoka et al., 1998; Blasina et al., 1999). An important kinase required specifically for this 
checkpoint is Wee1, known as the gatekeeper G2/M. CHK1 signals through WEE1 which 
phosphorylates and inactivates CDK1, a key driver of mitosis (O’Connell et al., 1997). WEE1 
is over expressed in many cancers allowing for the repair of otherwise fatal DNA aberrations 
in the absence of p53, which is commonly dysfunctional in cancer cells. It has been 
hypothesised that this represents a potential Achilles heel in cancer, with much current interest 
in WEE1 as a potential therapeutic target (Do et al., 2013; Matheson et al., 2016; Bukhari et 
al., 2019). These DDR checkpoint signalling pathways have evolved into order to prevent the 
transmission of aberrant genetic information, therefore, it is little wonder that the dysregulation 
of these components is associated with cancer. 
1.2.3. The restriction point  
The point at which cells no longer require growth factor signalling to progress in cycling is the 
restriction point, or R point, which resides in late G1 (fig. 1). In cell culture the removal of growth 
factors prior to the R point will prevent the progression into S-phase (Pardee, 1974). Once 
past this point, cells are irreversibly committed to DNA synthesis and thus no longer require 
mitogenic signalling for cell cycle progression. The molecular mechanisms regulating this 
checkpoint are incompletely understood. However, members of the retinoblastoma (RB) family 
and associated proteins are indicated to be important regulators  which will be discussed 
further in section 1.2.6 (Chi et al., 2017, p.3; Sage et al., 2000). Naturally, loss of R-point 
signalling is thought to be critical in cancer, as dysregulation would permit cells to proliferate 
in the absence of mitogenic signal (DelSal et al., 1996). 
1.2.4. Spindle checkpoint 
Undoubtably the most visually remarkable phase of the cell cycle is mitosis, the phase in which 
chromosomes can be observed aligning and segregating under a microscope (Salmon et al., 
1994). The spindle checkpoint acts to ensure proper chromosomal alignment before the 
segregation of chromosomes during anaphase. The mitotic spindle is a complex and dynamic 
bipolar network of protein filaments which operate as the machinery needed to separate 
chromosomes during mitosis (Musacchio and Hardwick, 2002). Mitosis can be subdivided into 
well-defined individual sequential phases; prophase, metaphase (sometimes subdivided into 
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prometaphase and metaphase), anaphase, and telophase (Walczak et al., 2010). In prophase, 
chromosomes condense, replicated centrosomes move towards opposite poles, and 
breakdown of the nuclear envelope initiates. The central alignment of chromosomes takes 
place in metaphase and prometaphase. In anaphase, sister chromatids separate at the 
centromere and begin to move apart, and in telophase, the final stage, chromatids have 
reached poles and individual nuclear envelopes begin to form (See figure 2)(Cooper, 2000b). 
Finally, the physical separation of cells proceeds, known as cytokinesis. 
 
Figure 2. Mitotic phases. During interphase chromatin is mostly decondensed, conversely, 
in prophase, chromatin becomes highly compact and the nucleolar envelope begins to break 
down. In prometaphase, the nuclear envelope is fully broken down, allowing bundles of 
microtubules (K-fibres) to connect the kinetochore of chromosomes to the spindle. 
Chromosomes are then uniformly oriented along the equator of the cell, defining metaphase. 
In anaphase A, kinetochore microtubules shorten, pulling chromatids apart towards poles, 
followed by anaphase B where interpolar and astral microtubules provide force that separates 
the poles. In the final phase, telophase, the nuclear envelope begins to reform, and chromatin 
begins to decondense. The cytoplasm and nuclei are then divided into individual daughter 
cells, constituting cytokinesis (Walczak et al., 2010). 
Improper chromosomal segregation during mitosis can promote aneuploidy and genetic 
instability (Rajagopalan and Lengauer, 2004). Cells therefore must tightly regulate 
segregation in order to prevent instability. The spindle assembly checkpoint (SAC) consists 
of machinery which ensures the correct attachment of microtubules to all chromosomes prior 
to anaphase onset. Chromosomes attach to microtubules via the kinetochore, a 
proteinaceous platform associated with the centromere, the structure connecting sister 
chromatids (McKinley and Cheeseman, 2016). The process of microtubule attachment to the 
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kinetochore during prometaphase is a stochastic process in which microtubules extend and 
retract until two kinetochores of a sister chromatid pair attach to opposite poles (Cleveland et 
al., 2003). It is critical that cells ensure segregation of chromosomes ensues only once 
proper metaphase plate orientation is achieved. The core components of this checkpoint 
complex, first elucidated in Schizosaccharomyces pombe, are Mad, Bub and Cdc20 
(Overlack et al., 2014). Importantly, Cdc20 is also a core component of the anaphase 
promoting complex (APC/C), which when active, targets the destruction of securin (Thornton 
and Toczyski, 2003). Securin is an inhibitor of separase, which initiates anaphase onset 
through the cleavage Scc1, a key protein involved in the complex which holds sister 
chromatids together, cohesin. Fundamentally the checkpoint seems to act through the 
quenching of the cytoplasmic pool of Cdc20 by unattached kinetochores, thus inhibiting 
APC/C function and downstream signalling (Yu, 2002; Cleveland et al., 2003). It is inherent 
that defects in this network sensitise cells to improper chromosomal segregation and genetic 
instability. Indeed, such components, when defective, have been shown to predispose 
individuals to cancer and contribute to tumorigenesis (Bharadwaj and Yu, 2004; Ryan et al., 
2012; Hanks et al., 2004).   
1.2.5. Cytoskeletal changes 
The cytoskeleton is a group of filamentous proteins which, (1) organise spatial arrangement 
within the cell, (2) generate the physical forces which facilitate changes in cell morphology, 
and, (3) biochemically and physically link the cell to the external environment (Fletcher and 
Mullins, 2010). This web-like network is a dynamic and adaptive set of structures, constantly 
rearranging during the lifetime of a cell. Polymers of specific proteins form three main distinct 
structures. These are microtubules, actin filaments and intermediate filaments (Hohmann and 
Dehghani, 2019).  
 
Microtubules are stiff tube-like protein filaments made up of αβ-tubulin polymers. These 
structures function as a network for intracellular transport, support cellular shape, and 
facilitate the segregation of chromosomes during mitosis (Roostalu and Surrey, 2017). 
Microtubules are highly active structures, constantly undergoing dynamic polymerisation and 
depolymerisation (Brouhard and Rice, 2018). This dynamic instability is essential to their 
function in capturing chromosomes during mitosis (Sacristan et al., 2018). Moreover, the 
mechanisms which underpin microtubule organisation, and thus mitosis, have been long 
recognised to display high sensitivity to changes in temperature (Engelborghs et al., 1976; 
Grzanka et al., 2008). The organisational centre of microtubule assembly during the cell 
cycle is the centrosome, which consists of two cylindrical centrioles surrounded by a mass of 
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proteins collectively known as the pericentriolar material (PCM). The PCM is responsible for 
the de novo formation of microtubules, known as microtubule nucleation (Job et al., 2003). 
Microtubule nucleation is critical in cell migration, division, maintenance of cell shape, and 
cilia formation (Job et al., 2003). During S-phase the centrosome duplicates exactly once in 
preparation for division. As cells enter mitosis, microtubule nucleation initiates from these 
complexes forming an antiparallel structure which is pushed apart by kinesin motor proteins 
to form the mitotic spindle (Wordeman, 2010). It’s not surprising that these structures are 
normally tightly regulated, and that aberrant centrosome amplification is often observed 
cancer. Indeed, work in drosophila melanogaster has demonstrated amplification can 
contribute to tumorigenesis (Basto et al., 2008). On the other hand, whether centrosome 
amplification is a cause or consequence of cancer in mammals is controversial. It is clear 
that amplification does cause oncogenic traits such as aneuploidy, invasion, and metastasis 
(Ganem et al., 2009; Godinho et al., 2014). A recent study from (Levine et al., 2017) 
provides compelling evidence that centrosome amplification can indeed drive cancer 
formation in mammals. The study implemented a murine model in which centrosome 
number could be amplified in the absence of additional genetic alterations and demonstrated 
the spontaneous development of tumours in multiple tissues.  
 
Intermediate filaments make up the major morphological framework in a cell and undergo 
drastic reorganisation during the cell cycle. As their name suggests, these diverse cytoskeletal 
structures are intermediate in their size relative to microtubules and actin filaments. They are 
encoded by over 65 genes (Herrmann et al., 2002). Mutation in subunit components therefore 
is generally better tolerated than in microtubules and actin filaments, which consist solely of 
tubulin and actin, respectively (Klymkowsky, 2019). Moreover, intermediate filaments are not 
directly involved in cell motility, rather playing a structural role in tissues and cells (Cooper, 
2000a). Naturally the breakdown of these foundations is essential during mitosis. An example 
of such is the deconstruction of the architectural network of the nuclear lamina. The nuclear 
lamina is a thick fibrous network associated with the nuclear envelope made up of lamin 
proteins which assemble into V-type intermediate filaments. Nuclear lamina disassembly is 
triggered by the activation of mitotic kinases such as CDK1 through the direct phosphorylation 
of lamin filament subunits. This mechanism was eloquently elucidated through in vitro 
catalysis assays and phospho-dead mutants blocking lamina disassembly during mitosis 
(Heald and McKeon, 1990; Peter et al., 1990).  
 
Actin filaments are the thinnest of the trio and are often crosslinked into complex networks 
(Blanchoin et al., 2014). These filaments have an extremely diverse array of physiological 
functions, often involving myosin motor proteins which move along actin filaments in an ATP-
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dependent reaction which strikingly resembles walking (Kodera and Ando, 2014). Actin-
myosin chemistry generates the mechanical force needed for muscle contraction, vesicle 
transport, and cytokinesis to just name a few processes. During cytokinesis, the cytoplasm is 
divided in two by a complex meshwork of these filaments and associated proteins known as 
the cell cortex (Reichl et al., 2008). Furthermore, the actin filament cytoskeletal network plays 
a defining role in cell cycle progression past the G1 checkpoint through linking extra cellular 
matrix (ECM) signal transduction (Forgacs et al., 2004).  
 
Regulation of the cell cycle is tightly linked to the adhesive interactions of cells with the ECM. 
Integrin transmembrane receptors and proteoglycans mediate this communication at specific 
lipid raft areas, known as focal adhesions sites, which directly link to the actin cytoskeleton 
(Burridge et al., 1990). Multiple components of mitogenic signal transduction networks have 
been demonstrated to directly link to this actin cytoskeleton, prime examples include 
phospholipase C and phosphatidylinositol kinase (Payrastre et al., 1991). Indeed, 
pharmacological aberration of actin structure leads to G1 cell cycle arrest in multiple cell types 
(Huang and Ingber, 2002; Lohez et al., 2003). Furthermore, actin cytoskeletal dynamics are 
tightly linked with metastasis. The epithelial to mesenchymal transition (EMT) is a tissue 
remodelling cellular programme initiated during development. During EMT, actin cytoskeleton 
cell-cell junction linkages in epithelium break down, allowing cells to migrate. Cancer cells 
hijack this physiological process in order to promote metastasis, in which actin plays a critical 
role. This is reflected by regular presence of upregulated actin-associated proteins during 
cancer EMT (Lamouille et al., 2014). 
1.2.6. Cyclins and cyclin dependent kinases 
The master regulators of eukaryotic cell cycle progression are cyclin dependent serine-
threonine kinases. The CDK catalysed phosphorylation of key substrates is central in ensuring 
major events are correctly orchestrated (Morgan, 1995). CDKs act as information processing 
nodes which integrate intracellular and extracellular signalling networks (Malumbres and 
Barbacid, 2009). CDK catalytic capacity requires their regulatory subunits; the cyclins, which 
are aptly named after their ability to drive cell cycling (Morgan, 1997). CDKs undergo 
constitutive expression, whereas specific cyclins oscillate at different cell cycle phases to 
activate their partner CDKs (Wright et al., 2019). Cyclins can be broadly divided into four 
classes, G1/S, S, M and G1 cyclins. G1 cyclins regulate entry into the cell cycle (Bertoli et al., 
2013). The Cyclin E family are expressed at the G1/S transition, Cyclin A in S phase and G2 
phase, and cyclin B in M phase (fig. 3)(Musgrove, 2006). D type cyclins pay a key role in G1 
phase initiation and are tightly regulated. Activation is complex and can occur at both the 
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transcriptional and post-transcriptional level (Blagosklonny and Pardee, 2002). Classically, 
cyclin D1 is transcriptionally activated via the Ras-Raf-MEK-ERK cascade in response to 
mitogenic signalling (Lavoie et al., 1996). Cyclin D is then available to bind with CDK4/6 and 
phosphorylate a number of downstream substrates. A key target of this complex is RB, a 
tumour suppressor commonly dysfunctional in many cancers (Dunn et al., 1988). The evolved 
complexity of signalling and tight regulation around this node of cell cycle initiation is pertinent 
given aberrant cell cycle entry promotes oncogenesis (Malumbres and Barbacid, 2009). 
Further highlighting importance of tight regulation, cyclin D mutation and overexpression is 
commonly seen in a range of cancers (Musgrove et al., 2011). 
 
Figure 3. Schematic representation of cyclin concentration over the course of the cell cycle 
(figure adapted from Morgan and Roberts, 2002). 
Provided mitogenic signalling is sustained, CyclinD-CDK4/6 remains catalytically active and 
phosphorylates RB (Rubin, 2013). In the absence of phosphorylation, RB inhibits E2F, a key 
transcription factor that upregulates a plethora of genes involved in DNA synthesis and 
nucleotide metabolism and thus licences cycle progression into S phase (Lundberg and 
Weinberg, 1998). RB phosphorylation releases E2F, which is then free to bind to its target 
promoters and upregulate key genes, an important one to note being cyclin E. Once 
synthesised, cyclin E then binds and activates CDK-2 which phosphorylates a number of 
substrates, one being RB, thus forming a feedback loop (Rubin, 2013). Sequential 
phosphorylation of RB by cyclinD-CDK4/6 and cyclinE-CDK-2 is required for complete 
hyperphosphorylation of RB and cell cycle progression past the restriction point (Lundberg 
and Weinberg, 1998). Once past the restriction point, the cell is irreversibly committed to DNA 
replication and cell cycle progression (Blagosklonny and Pardee, 2002). It is no surprise 
therefore that restriction point signalling components are commonly mutated and dysfunctional 
in cancer (Malumbres and Barbacid, 2001). In late G1 phase cyclin A concentration increases 
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playing essential role in S phase initiation, causing phosphorylation of key DNA replication 
components by activating CDK2. These levels rise and don’t start decline until mid G2 phase 
(Erlandsson et al., 2000). Interestingly, cyclin A functions in both S and M phase by associating 
with functionally distinct CDKs 1 and 2 (Pagano et al., 1992). In G2 A type cyclins are degraded 
and cyclin B is actively expressed activating CDK1 which phosphorylates a number of 
substrates involved in driving M phase processes such as chromosomal condensation and 
nuclear lamina breakdown (McHugh and Heck, 2003; Gavet and Pines, 2010). 
1.2.7. Ubiquitin and the cell cycle 
Selective and orderly protein degradation via the ubiquitin-proteasome system ensures correct 
cell cycle event timing and directionality. Ubiquitin is a small, highly conserved, ubiquitously 
expressed 76 amino acid protein that post-translationally marks proteins, either as a single 
ubiquitin moiety or as polyubiquitin chains (Cappadocia and Lima, 2018). Ubiquitination of 
proteins can mediate cellular localisation, function and stability (Pickart, 2001). Ubiquitin is 
covalently attached to lysine residues on a target protein and itself contains seven lysine 
residues, each of which serves as a potential linkage site for ubiquitin chain polymerisation. 
The linear and branching linkage possibilities provide immense structural diversity for effector 
protein recognition (Deol et al., 2019). For example, K11 or K48 linkages adopt a compact 
conformation and usually lead to proteasomal degradation. In contrast, K63/M1 linkages 
specify a more open configuration and are involved in proteasome-independent functions such 
as DNA damage repair signalling (Belzile et al., 2010; Metcalf et al., 2014). 
 
The tagging of target proteins with ubiquitin is a highly ordered process orchestrated by the 
sequential action of three enzymes. The process begins with E1 activating enzymes which 
activate ubiquitin in an ATP-dependent two-step reaction. E1 forms a thiol ester with the G76 
carboxyl of ubiquitin priming the C terminus for nucleophilic attack (Cappadocia and Lima, 
2018). E2 conjugating enzyme then transiently carries activated ubiquitin as a thioester and 
E3 ligase facilitates the addition of ubiquitin to a given substrate, most commonly forming an 
isopeptide bond between the substrate and ubiquitin (fig. 4)(Pickart, 2001). This process can 
be repeated, leading to poly-ubiquitylation, although a further novel E4 ubiquitylation factor 
may be required for certain linkages (Hoppe, 2005). Whilst E1 and E2 are generally involved 
in activating and carrying ubiquitin, E3 ligases are considered responsible for substrate 
specificity. Over 600 E3 domain proteins have been characterised in the human genome 
(Deshaies and Joazeiro, 2009). The majority of which form multi-subunit complexes, 
facilitating substrate recognition via complexed binding domains, representing a further layer 
of ubiquitin signalling complexity (Berndsen and Wolberger, 2014).  
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Figure 4. The ubiquitin cycle ubiquitylation is carried out by the sequential action of ubiquitin 
activating (E1), conjugating (E2) and ligating (E3) enzymes. Ubiquitin can be removed by 
deubiquitylases (labelled DUB). E3s can be subdivided into categories based on their 
structure and catalytic chemistry (RING E3 displayed). Blue circles represent ubiquitin (Figure 
adapted from Borg and Dixit, 2017). 
 
The dysregulation of this system is often seen in cancer. A key example is the overexpression 
of S-phase kinase associated protein 2 (SKP2). SKP2 is a core component of the SKP1-
CUL1-F-box (SCFSKP2) E3 ligase complex involved in the recognition and ubiquitin mediated 
proteasomal degradation of the G1 phase checkpoint protein p27 (Nakayama and Nakayama, 
2005). p27 is essential in G1 cell cycle arrest in response to DNA damage (Cuadrado et al., 
2009). It is pertinent therefore that many cancers select for overexpression of this component, 
promoting proliferation and genomic instability (Harper et al., 2002). SCF plays a central role 
in cell cycle control signalling. Dynamic interplay between ubiquitylation and phosphorylation 
form regulatory mechanisms and feedback loops (Swaney et al., 2013). Cyclin D is an 
example of phosphorylation dependent ubiquitylation directed proteasomal degradation, and 
contains a so called phosphodegron (O. et al., 2009). DNA damage activates MAP kinases 
which phosphorylate cyclin D facilitating SCFSKP2 recognition and subsequent ubiquitylation 
and degradation (Santra et al., 2009; Shan et al., 2009). The SCF core complex is in part 
regulated through variable substrate recognition subunits. SKP2 is the most well understood 
of these subunits with maximal expression seen at S and G2 phases. In addition to p27, SKP2 
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targets other related cyclin kinase inhibitors and cyclins, promoting progression through these 
phases (Nakayama and Nakayama, 2005). 
 
A further important E3 ligase involved cell cycle regulation is the anaphase promoting 
complex/cyclosome (APC/C). APC consists of ~12 subunits and is regulated through 
activating subunits cell division cycle protein 20 (CDC20) and APC activator protein CDH1 
(CDH1), each conferring diverse substrate specificities (Harper et al., 2002). Shortly before 
mitosis, CDC20 is phosphorylated by CDK1, which in part facilitates its interaction with the 
core APC complex (Kramer et al., 2000). Once all chromosomes are successfully attached to 
the bipolar mitotic spindle, the spindle assembly checkpoint, described earlier, is satisfied and 
CDC20 binding to APC induces the recognition and ubiquitin mediated degradation of cyclin 
B and securin thus promoting anaphase. Moreover, activation of APC through CDH1 binding 
plays a pivotal role in G1 phase cycle progression by maintaining low CDK activity, in addition 
to, regulating the transition from G1 phase to S phase via the degradation of DNA replication 
origin regulation factors geminin and CDC6 (Petersen et al., 2000; McGarry and Kirschner, 
1998). Both APC activators play significant distinct roles in tumorigenesis. CDC20 is 
commonly upregulated in cancers and inhibition has been shown to reduce tumour growth 
(Manchado et al., 2010). Conversely, a reduction in CDH1 expression is common in many 
cancers suggesting a tumour suppressor role (Fujita et al., 2008b, 2008a).  
1.3. Monitoring the cell cycle  
In order to investigate cancer cell cycle regulation it is essential to have a means of monitoring 
cell cycle state (Price et al., 2016). Early studies of cell division involved observing 
morphological changes of cells, such as chromatin state changes during mitosis, thus limiting 
phase discrimination to interphase and mitosis (Nurse, 2000). Since then a myriad of 
techniques has emerged, each with their caveats and nuances (Schorl and Sedivy, 2007). 
Current monitoring technology can be divided into two categories; snapshot-type approaches 
and continuous live monitoring methods. Snapshot methods generally require cell 
synchronisation and/or fixation and provide limited temporal information (Davis et al., 2001). 
These include techniques which quantify DNA synthesis or content and immunohistochemical 
staining of cell cycle markers. Although flawed by their inability to monitor live cells, these 
classic methods are an important spanner in the investigative toolkit. The second category, 
live cell continuous monitoring methods, allow for the observation of dynamic changes in cell 
behaviour (Jensen, 2013). 
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1.3.1. Cell stains  
Treating fixed cells with dyes and stains were among the earliest innovations used to analyse 
cell cycle state. A prominent early example is Feuglen stain (Biesterfeld et al., 2011). In 1924 
German physiologist Robert Feulgen developed an assay which would lead to repeated 
fundamental discoveries in biology over the coming years. The assay used HCl hydrolysis to 
generate free aldehyde groups in DNA backbones followed by the staining of these groups in 
a coloured reaction developed over 50 years earlier (Schiff, 1866). This reaction then went on 
to aid in the establishment of the DNA/chromosome 1:1 relationship, DNA content doubling 
during mitosis, and provided a basis for early flow cytometry (Reviewed by Chieco and 
Derenzini, 1999, pp.345–358). Further advancement in cell cycle analysis came following the 
development of fluorescent DNA-intercalating dyes and deoxyribonucleotide analogs such as 
Hoechst and bromodeoxyuridine (BrdU) respectively. Hoechst’s low toxicity allowed for DNA 
staining of live cells and the incorporation of BrdU with the DNA of S-phases cells later 
provided a means of DNA replication temporal quantification through pulse-chase labelling 
(Humphreys, 2015; Latt, 1974). Shortly thereafter, the development of a BrdU specific 
antibody resulted in a more efficient means of BrdU incorporation detection (Gratzner et al., 
1975). In recent years cell staining’s have evolved considerably. There are now vast 
catalogues of cell-permeable organelle specific fluorescent dyes, allowing one to analyse 
multiple subcellular structures with live-continuous microscopy methods. Important to note 
however, that imaging of these molecules can lead to highly cytotoxic breakdown products, 
thus limiting application (Ettinger and Wittmann, 2014). 
1.3.2. Cell counting   
Accurately counting the number of cells in a sample is of importance to a diverse array of 
disciplines. From colony counting microbes in an agar dish, to the quantification of leukocytes 
in a blood sample, cell counting’s applications span the breadth of the life sciences. 
Furthermore, the quantitative analysis of cell proliferation through cell counting is a corner 
stone of both cancer biology and pharmacological screening (Romar et al., 2016). Counting 
cancer cells before and after a perturbation of interest, hypoxic exposure or drug treatment for 
example, can provide an important and economical initial outlook of the impact of the specific 
perturbation on proliferation rate (Fujimoto-Ouchi et al., 2007; Morten et al., 2016). The 
haemocytometer is one of the most rudimentary tools used to count cells. The instrument 
consists of two glass slides with precise markings which allow the user to manually count the 
number of cells in a predefined volume of solution under a microscope, thus producing a 
cell/ml approximation (Absher, 1973). Given its low-cost and ease of use the haemocytometer 
has earned its place as the cornerstone method of cell counting. Despite it being over 100 
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years since its invention, one can be found in the draw of practically every cell biologists lab 
across the globe (Vembadi et al., 2019). This method is relatively low throughput however, 
thus automated cell counting methods have evolved and become popular in modern life 
sciences. 
 
There are three main automated cell counting methods used to count cells. These are coulter 
counting, flow cytometry, and digital imaging combined with automated cell counting (Vembadi 
et al., 2019). The coulter counter is used most prevalently in clinical haematology (Mei et al., 
2012). The device works by individually passing cells through an orifice and measuring 
electrical impedance. This provides direct information on cell size, and thus is able to 
discriminate between lymphocytes and erythrocytes. From a cell cycle biologists perspective, 
Coulter counting has proven useful in investigating changes in mass, volume and density of 
cells during the cycle (Bryan et al., 2010; Ondracka et al., 2018). The counter is limited in cell 
cycle biology, however, as is unable to accurately differentiate between cell cycle phases.  
 
In flow cytometry cells are passed individually through an aperture in a similar way to Coulter 
counting. Although rather than measuring impedance, flow cytometers use laser beams to 
gather information on cell characteristics (McKinnon, 2018). As a cell passes through the 
aperture, laser light is scattered and gathered by a detector (Ormerod and Imrie, 1990). In 
addition to analysing cellular parameters, many cytometry systems also have the capability to 
physically separate cells based on their optical output, so called fluorescent activated cell 
sorting (Sergent-Tanguy et al., 2003). Moreover, the multiparametric capabilities of flow 
cytometry deliver considerable advantages over coulter counting. Moderns systems are able 
to analyse up to 20 parameters through laser scattering and the excitation/emission of 
fluorescent probes (Vembadi et al., 2019). In cell cycle investigations Hoechst DNA staining 
is often used alongside flow cytometry to discriminate between cells in G1 and S/G2 phases 
(Kim and Sederstrom, 2015). Standard flow cytometry methods are unable to provide dynamic 
cell cycle phase resolution or visualise cell morphology. However, automated image analysis 
of real-time confocal microscopy time lapse imaging can over-come such limitations (Ford et 
al., 2018). As such, this method of counting will be employed in this study. 
1.3.3. Fucci 
Fluorescence microscopy underwent a resurgence following the purification and 
characterisation of jelly fish green fluorescent protein (GFP) (Morise et al., 1974). Years later, 
in 1992, Prasher and colleagues went on to successfully genetically engineer GFP into living 
cells, demonstrating the transgenic expression of a fluorescent probe for the first time (Prasher 
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et al., 1992). This advancement blew open the possibilities of fluorescence microscopy by 
allowing almost any protein to be fluorescently tagged and imaged with fine temporal and 
submicrometer spatial resolution (Thorn, 2017). Furthermore, through protein engineering, the 
palette of colours available has expanded to almost any colour imaginable, allowing multiple 
labels to be imaged simultaneously (Greenwald et al., 2018). Despite this range, certain 
constraints must be considered when designing an imaging pipeline. When imaging multiple 
fluorochromes simultaneously, the experiment must be designed to avoid excitation and 
emission peak spectral overlap, otherwise one fluorochrome may be detected in another’s 
channel (North, 2006). This generally limits scanning laser confocal imaging to 4 colours at 
once. Although with careful fluorochrome selection and specialist set-ups, 6 colour is possible 
without the need for deconvolution (Eissing et al., 2014). 
 
Cell cycle biologists took advantage of this capability to fluorescently tag almost any gene and 
designed the fluorescent ubiquitination-based cell cycle indicator (Fucci). Asako Sakaue-
Sawano and colleagues (2008) linked orange fluorescent protein mKO2, and green mAG, to 
Cdt1 and geminin respectively. As aforementioned, these proteins oscillate reciprocally during 
the cell cycle due to timed and co-ordinated proteasomal degradation catalysed by E3 ligases 
SCF and APC (fig. 5A). Geminin levels are highest during S, G2 and M phases, and Cdt1 is 
highest during G1. Thus, Fucci can accurately and reproducibly discriminate between cells in 
G1 and S/G2/M phases (See fig 5B) (Sakaue-Sawano et al., 2008).  
 
 
Figure 5. Fucci (a) Cell cycle regulation by oscillating E3 ligases SCF and APC results in 
Cdt1 and Geminin bistability between G1 and S/G2/M phases. (b) Fluorescent probes label 
G1 phase cells in red, and S/G2/M phase cells in green. 
Since its creation, Fucci has been repeatedly modified and upgraded. Notable adaptations 
include Fucci2, which replaced previous fluorochromes with mCherry and mVenus resulting 
in better colour contrast (Abe et al., 2013). Fucci2a overcame issues with varied expression 
between probes by incorporating both into one polycistronic transcript by fusing the Thosea 
asigna virus 2A (T2A) self-cleaving peptide between probes (Mort et al., 2014a). One of the 
more recent modifications to Fucci involved the redesign of the truncated Cdt1 probe to include 
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the PIP box motif and exclude Cy motif (fig 6A-B). By modifying Cdt1 in this way the probe is 
no longer recognised by SCF, but rather by the S-phase specific E3 ligase CUL4Ddb1 (fig. 6A) 
(Sakaue-Sawano et al., 2017). The resultant biosensor, coined Fucci(CA), produces a distinct 
tri-colour separation of G1, S and G2/M phases (see fig 6C). In this study we intend to modify 
and extend Fucci(CA) in order to facilitate novel time-lapse confocal cell cycle imaging 




Figure 6. Fucci(CA) (a) CUL4 sensitive hCdt1 probe (b) APC sensitive hGeminin probe (c) 
modified probe provides tri-colour G1, S and G2/M phase discrimination.  
1.4. Disrupting the cell cycle 
Cancer treatment aims to rid the body of cancerous cells through their removal and/or 
destruction (Huang et al., 2017). The efficacy of surgical removal on its own is limited. 
Removal of metastases and microscopic disease often present an unworkable surgical 
challenge and surgery can lead to an increased risk of micrometastatic growth (Tohme et al., 
2017). For curative treatment cancer destructive modalities are generally needed. The most 
prevalent systemic therapeutic strategies involve disrupting the cell proliferation or DNA 
synthesis thus leading to the destruction of cancer cells (Khanna, 2015).  
1.4.1. Chemotherapy 
During the 1st world war both sides engaged in the production and experimentation of 
poisonous gases. One notably effective agent, di-(2-chloroethyl)sulphide, otherwise known as 
mustard gas, was recognised to cause bone marrow aplasia and gastrointestinal tract 
aberrations (Brookes, 1990). This cytotoxic activity was later discovered to be due to the 
agent’s DNA alkylating activity (Brookes and Lawley, 1961). This discovery serendipitously 
provided a basis for chemotherapeutic anti-cancer treatments and gave birth to the era of 
chemotherapy (Falzone et al., 2018; Gilman, 1963).  
A B C 
 18 
 
Chemotherapeutic agents can broadly be split into two categories; cytotoxic and targeted 
therapies (Masui et al., 2013). Cytotoxic drugs are the more traditional of the two therapies 
and generally act through disrupting DNA synthesis or microtubule regulation (Mitchison, 
2012). It is thought that cytotoxic chemotherapies cancer killing specificity is due to preferential 
destruction of rapidly dividing cells (Brunton et al., 2006). This is supported by a myriad of 
evidence, including the drug’s effect on quickly dividing normal cell types, which can result in 
severe side effects such as alopecia, diarrhoea, vomiting, itchiness and cytopenia to name 
just a few (Liu et al., 2015). Interestingly however, cytotoxic regimens have been shown to be 
effective in shrinking tumours with relatively low proliferation rates, contradicting what is 
understood to be cytotoxic chemotherapies specificity mechanism (reviewed by Mitchison, 
2012).  
 
Cytotoxic chemotherapy can further be broadly divided into alkylating agents, antimetabolites, 
anti-microtubule agents, topoisomerase inhibitors and cytotoxic antibiotics. Alkylating agents 
are the most common and earliest to be used to treat cancers and generally function by 
covalently crosslinking strands of DNA in cycling cells resulting in cell death (Ralhan and Kaur, 
2007). Antimetabolites are molecules which structurally resemble purine and pyrimidine 
nucleotide bases and disrupt DNA synthesis by either inhibiting enzymes associated with DNA 
synthesis, or their incorporation into DNA resulting in dysfunction and cell death (Lind, 2008). 
Tubulin binding drugs, such as paclitaxel, prevent microtubule assembly or disassembly and 
thus disrupt chromosome separation and cell division (Weaver, 2014). Topoisomerases 
ameliorate topological DNA aberrations which occur during transcription, replication, 
recombination and chromatin remodelling by cleaving and re-joining DNA (Champoux, 2001). 
These enzymes are often upregulated in cancer and their inhibition can prevent cell cycling 
(Pommier, 2013). Cytotoxic antibiotics, such as anthracyclines, are thought to induce cell 
death through multiple mechanisms (Lind, 2008). The second broad category of drugs; 
targeted therapies, differ from traditional cytotoxic chemotherapy in that they inhibit specific 
molecular targets in cancer rather than broadly effecting cell division. These therapies include 
small molecule inhibitors, monoclonal antibodies and immunotherapy (Walter and Ahmed, 
2018).   
 
Chemotherapeutic regimens are predominantly designed to include a combination of drugs 
(Emil Frei and Eder, 2003). A single drug is often not a sufficient treatment due to acquired 
drug resistance (Pritchard et al., 2012). Combinatorial therapy can be designed to modulate 
multiple signalling cascades in order to overcome acquired drug resistance and maximise 
patient response (Hu et al., 2016). Moreover, when administering multiple drugs, the 
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therapeutic effect can by synergistic, whilst toxicity remain independent, allowing a higher 
cumulative dose of drug to be administered (Pritchard et al., 2012). The vast catalogue of 
approved agents combined with neoplastic disease heterogeneity have resulted in 
chemotherapeutic regimen design becoming somewhat of an art form. Clinicians prescribe a 
complex variable cocktail of agents of a particular composition depending on tumour 
classification and a myriad of other clinical parameters (Ibrahim et al., 2012). Despite such 
innovation and ingenuity systemic chemotherapy practically always leads to concerning side 
effects (Nurgali et al., 2018). Therefore, there is drive much in the oncological science 
community to develop novel therapeutic modalities to reduce toxicity (Alexander et al., 2017; 
Hedigan, 2010). 
1.4.2. Radiotherapy  
When Wilhelm Conrad Röntgen first discovered X-rays in 1895 the field of radiation oncology 
was born (Baskar et al., 2012). Very shortly after this discovery the clinical effectiveness of X-
rays was demonstrated by the treatment of a patient with breast cancer using radiation 
(Gianfaldoni et al., 2017). Shortly thereafter, Marie Sklodowska-Curie and husband Pierre 
Curie discovered radium as a radiation source. The following work on the physiological effects 
of radium would later award Marie Curie a Nobel prize (Diamantis et al., 2008). Radiation 
oncology has since developed into a vital wrench in the cancer treatment toolbox. Radiation 
therapy (RT) is used to treat >50% of cancers and is highly cost effective, incurring just ~5% 
of total cancer treatment cost (De Ruysscher et al., 2019; Ringborg et al., 2003).   
 
RT functions by applying ionizing radiation to cancer cells in order to destroy them. Ionizing 
radiation deposits energy in the form of electrically charged particles in the tissues it passes 
through, damaging DNA, and inducing apoptosis or blocking cell division (Jackson and Bartek, 
2009). RT high energy particles are damaging to both normal and cancer cells, however. Thus, 
the design of RT application aims to maximise the dose at the site of the tumour and minimise 
normal cell exposure (Baskar et al., 2012). RT is generally administered in one of two ways. 
The most common method of administration is done by using high energy rays delivered into 
the body from an external source. Many methods of delivery of this category have been 
developed in order to maximise the dose to cancer cells and minimise the dose to normal 
cells. One such approach is intensity-modulated radiation therapy (IMRT). IMRT uses 
radiation beams from multiple angles focused to a precise point at the tumour. This approach 
maximises the dose at the tumour, whilst minimal dosage is delivered to the normal tissues, 




Figure 7. Intensity-modulated radiation therapy (IMRT) functions through the precise 
focusing of radiation from multiple beams meeting at the site of the tumour (Figure adapted 
from Baumann et al., 2016).  
The second less common mode of administration is brachytherapy, which involves radioactive 
material being placed inside the body. This modality is predominantly used to treat 
gynaecological and prostate malignancies (Banerjee and Kamrava, 2014; Porter et al., 1995).  
 
Despite RT’s modern technological advancements a substantial proportion of patients 
experience radiation resistance and cancer reoccurrence (Kim et al., 2015). In radiation 
resistance, cancer cells adapt and are able to tolerate the molecular changes induced by RT. 
This process is complex and involves multiple factors and mechanisms (Tang et al., 2018). 
Furthermore, despite advances in delivery, RT is often associated with toxicity and long-term 
side effects. Side effects generally depend on the site of administration. These include 
impairments to bone growth, hair loss, reproductive disorders, gastrointestinal damage, 
cardiac toxicity and secondary cancer to name a few (Reviewed by De Ruysscher et al., 2019). 
Thus, there is much interest and effort in the development of novel combinatorial therapies to 
improve the therapeutic ratio of RT in order to reduce toxicity and side effects (Baskar et al., 
2012). 
1.4.3. Hyperthermia therapy 
Hyperthermia therapy (HT) aims to raise the temperature of a specific tissue, or the whole 
body, to temperatures usually between 39 and 45 oC to treat cancer (Behrouzkia et al., 2016). 
The application of heat to treat disease can be dated back as far as ancient Egypt. Papyrus 
scroll records describe the use of so called ‘fire drills’ used to treat breast cancer (Watmough 
and Ross, 1986). Moreover, records describe medical practitioners in ancient India and China 
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making use of hyperthermia range temperature treatments to treat tumours (Gas, 2017). In 
modern medicine, however, HT is predominantly used as an adjunctive and acts to increase 
the therapeutic ratio of conventional therapy. That is, combining HT with chemo or RT to 
increase the efficacy of a specific dose and reduce overall toxicity (Horsman and Overgaard, 
2007). HT is commonly used in clinic, with a plethora of clinical trial outcomes being reported 
in recent years (Arjona-Sánchez et al., 2018, 2018; Koole et al., 2020; Ohguri et al., 2018). 
Despite clinical application, the effect of HT on cancer cell cycle dynamics is poorly 
understood. Thus, an increased understanding of the parameters involved in HT may aid in 
the design of novel adjunctive therapeutic regimens. 
 
Clinical application generally falls under three categories, whole body, regional or local (van 
der Zee, 2002). Whole body HT is used to treat metastatic disease. Treatment of this type 
typically involves patients being anaesthetised and incubated in a flexible infra-red chamber 
(Jia and Liu, 2010). In regional HT the goal is to heat a limb or a particular body cavity. 
Hyperthermic chemoperfusion is a regional therapy that has shown marked success in treating 
peritoneal metastases. This involves filling the abdominal cavity with pre-heated 
chemotherapeutic agents (Goodman et al., 2016). Methods used for local therapy aim to 
specifically heat tumours and can be divided into superficial and deep tissue techniques. 
Superficial treatments are well developed and generally involve heating through the precise 
application of a microwave emitting contact medium at the skin surface (Maccarini et al., 
2004). Specifically heating a tumour deep within the body is more complicated task. Current 
methods used in clinic involve applying micro or ultrasound-waves from multiple sources 
focused to a point at the site of the tumour (Datta et al., 2015). This method has proven limited 
however, due to heterogeneous heat distribution and difficulties with overheating. Currently 
there is much interest in the development of magnetic nanoparticles (MNP) as a means of 
delivering site specific heating (Giustini et al., 2010; Hedayatnasab et al., 2017). This 
approach aims to target magnetic nanoparticles, which is a key challenge of the approach, to 
tumour sites and uses an alternating magnetic current to raise the temperature of the particles 
thus heating the surrounding tumour. An interesting targeting approach to note, which has 
shown efficacy in animal models, functions through hijacking the propensity of phagocytes to 
engulf nanoparticles and infiltrate tumours as a novel delivery system (Toraya-Brown et al., 
2013).  
 
Despite decades of investigation the effects of HT on tumours is not well understood. Selective 
tumour cytotoxicity in vivo is suggested to be in part to be due to differences between tumour 
and normal tissue physiology (van der Zee, 2002). Tumour vasculature is chaotic and 
unevenly distributed, which is attributed to the rate of angiogenesis often falling behind the 
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growth of rapidly proliferating neoplastic cells (Nagy et al., 2009). Consequently, tumour 
vasculature displays high resistance, fragility, and reduced blood flow, which leads to areas 
of tumour deprived of oxygen and glucose (Hanahan and Weinberg, 2011). Many studies have 
shown that moderate HT (41.5-42.5 oC) can significantly increase perfusion in tumours, thus 
increasing pO2 (reviewed by Song et al., 2001). This reduction in hypoxia is thought to be an 
important mechanism behind HT’s dose lowering effects on RT, given molecular oxygen is a 
potent radiosensitiser (Rockwell et al., 2009). Moreover, an increase in perfusion may lead to 
more efficient drug delivery, which is suggested to be partly responsible for HT’s additive 
effects to chemotherapy (van der Zee, 2002).  
 
In addition to these effects described above, HT can stimulate immunological attacks on 
tumours. The heat shock proteins (HSP) are a group of chaperone proteins that are induced 
in response to an array of physical and chemical cellular stresses. HSPs aid cell survival 
through chaperone activity and inhibition of caspase activation (Beere, 2004). The major 
orchestrater of HSP activation is transcription factor heat shock factor-1 (HSF-1). HSF-1 
undergoes constitutive expression and exists sequestered in an inactive state in the cytoplasm 
of unstressed cells. Once cells are heated, proteins begin to misfold, which signals the 
activation of HSF-1 through the depletion of the chaperone involved in assembling the HSF-1 
inhibitory complex (Shamovsky and Nudler, 2008). HSF-1 is then free to trimerise and 
upregulate the expression of a plethora of heat shock genes (Voellmy, 1994). In addition to 
assisting in protein folding, HSP complexes can directly elicit an anti-tumour immune 
response. Heat stressed tumour cells release heat shock protein 70 (HSP70) in complex with 
tumour-derived peptides into the extracellular space. These particles are then able to stimulate 
dendritic cell maturation and activation, which in turn prime and activate tumour specific 
cytotoxic T lymphocytes (fig. 5) (Frey et al., 2012). Indeed, autologous administration of these 
tumour derived complexes has been shown to elicit a specific immunological response, thus 




Figure 8. HT renders tumour cells immunogenic. Following hyperthermia treatment, 
protein aggregation and misfolding induces the unfolded protein response (UPR). In this 
response, heat shock protein 70 (Hsp70) is upregulated, leading to increased surface Hsp70. 
In addition, hyperthermia treatment increases intracellular tumour antigen (Ag) levels. 
Following a second stress signal from conventional therapy for example, tumour cell necrosis 
is induced, which releases Hsp70/Ag complexes into the extracellular space. Exosomal 
Hsp70/Ag complexes are also released.  The exosome and free Hsp70/Ag complexes activate 
and attract dendritic cells (DC), which present tumour Ag and induce immunogenicity by 
priming cytotoxic T lymphocytes (Figure adapted from Frey et al., 2012). 
Early studies investigating the basic principles of in vitro hyperthermic cellular death 
uncovered a dose and time dependent relationship between a range of 41 oC and 47 oC. 
Moreover, the ability of HT to induce cell death is markedly higher ≥ 43 oC (Hildebrandt and 
Wust, 2007). A further observation is the tendency of cells to develop a thermotolerance. If 
cells are cooled to 37 oC between heat treatments a reduction in cell killing is observed. This 
adaptation is not inherited, and is thought to be a result of heat shock proteins and other 
processes regulated through post-translational modification (Ohnishi, 2016). Another 
pioneering in vitro discovery was the propensity of HT to sensitise tumour cells to RT and 
chemotherapy. Although incompletely understood, this phenomena is thought to occur due to 




The topic of differences in HT sensitivity between normal cells and cancer cells is one of 
complexity. The vast majority of studies aim to investigate intrinsic differences in HT sensitivity 
as an adjunctive with chemotherapy and/or RT. Differences in sensitivity to HT alone are 
somewhat controversial. Mixed data are available for both the support and contradiction of 
autonomous cellular sensitivity differences. A review Van der Zee and colleagues (2002) 
suggested the data point towards there being “no intrinsic differences between hyperthermia 
sensitivity of normal and tumour cells except for haematological malignancies”. Conversely, a 
review from Chi-Dug Kang and Sun-Hee Kim(Kang and Kim, 2016)stated “many preclinical 
and clinical studies have shown that cancer cells are more sensitive to moderate hyperthermia 
than normal cells”. Interestingly, both reviews lack cited literature to support their statements. 
Furthermore, Kanwal Ahmed and colleagues (2015) stated in their review of HT apoptosis 
induction in cancer that generally cancer cells and normal cells bear no intrinsic differences in 
HT sensitivity. Oddly, the study cited to support this claim contains no relevant data, only data 
from the analysis of various breast cancer cell lines (Brade et al., 2003).  
 
A recent bioinformatics study boldly states that it has been known for over three decades that 
tumour cells are significantly more sensitive to mild hyperthermia than normal cells (Amaya et 
al., 2014). Although similarly, the literature cited to support this understanding contains no 
supporting data (Habash et al., 2006a, 2006b), only a sweeping statement, cited by another 
study (Dickson and Calderwood, 1980), which cites an investigation that carried out HT cell 
survival assays of Chinese hamster ovary (CHO) cells at varying pH concentrations to mimic 
the acidic environment of tumour cells (Freeman et al., 1977). As CHO cells do not represent 
true tumour cells this approach carries obvious limitations, thus, drawing a reasonable 
conclusion on the question of intrinsic differences could be considered unsuitable. A recent 
study demonstrated that immortalised keratinocytes are significantly more resistant to HT 
when compared with melanoma cells (Mantso et al., 2018). Although whether this is a 
characteristic of differences in sensitivity between cell types or neoplasticity remains 
unanswered. It is clear therefore, that the question of differences in HT sensitivity between 
neoplastic and non-neoplastic cells is one that is poorly understood and warrants further 
investigation. 
 
It’s been long recognised that cell cycle compartments vary in their sensitivity to hyperthermia. 
In the 1970s is was shown that cells in S-phase present a sensitivity to hyperthermia and the 
treatment therefore induces chromosomal irregularities (Dewey et al., 1971). Cells in M phase 
display the highest sensitivity to hyperthermia, with M phase cells undergoing microscopically 
observable aberrant mitotic apparatus formation (Hildebrandt and Wust, 2007), and HT 
treated lung cancer cells undergo cell death via mitotic catastrophe (Pawlik et al., 2013a). 
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Furthermore, it has been shown that cancer cells exposed to HT arrest in G2/M phase of the 
cell cycle, and given a sufficient temperature and treatment duration, will undergo apoptosis 
in a ATR-Chk1 dependent manner (Furusawa et al., 2012). Further, Amaya and colleagues 
(2014) found that breast cancers cells, but not mammary epithelial cells, accumulated in G2/M 
phase following HT treatment. Despite intensive research it is not understood which of the  
three apoptosis pathways; intrinsic, extrinsic, or the nascently elucidated endoplasmic 
reticulum intrinsic pathway (Sankari et al., 2012), are activated by hyperthermia (Reviewed by 
Ahmed et al., 2015).  
 
Differences in cell cycle dynamics in response to HT between cell types are understudied 
and poorly understood. As mentioned earlier, various aspects of the cytoskeleton, 
particularly the polymerisation of microtubules and actin, are sensitive to changes in 
temperature. It was also described how microtubule and actin dynamics are key to cell cycle 
progression. In particular, the dynamic instability of microtubules is required for chromosome 
capture and therefore successful progress through mitosis. Moreover, it was detailed how 
the actin cytoskleleton is involved in the G1/S checkpoint and extensive remodelling of actin 
is required for mitosis and cytokinesis. We therefore hypothesize that a disruption of 
cytoskeletal dynamics by heat treatment will lead to cell cycle aberrations in G1/S and 
mitosis. These aberrations may lead to cancer-specific effects due to cancer cells generally 
cycling more rapidly, and therefore will be more susceptible to cell-cycle disruption. To 
investigate, we set out to design novel Fucci based biosensors and engineer them into a 
range of cell types before exposing these cells to HT relevant temperatures whilst 
simultaneously carrying out time-lapse confocal microscopy. Such analysis may uncover 
novel differences in cell cycle compartment sensitivity between cell types. Also, it is possible 
that the molecular components regulating microtubule and actin dynamics will be 
dysregulated in cancer cells, which may be responsible for their sensitivity to changes in 
temperature. In addition, the mitotic regulators previously described to show altered 
expression in response to HT by Amaya (2014) and colleagues may confer cancer vs 
normal and cancer type/subtype specific thermosensitivity. We therefore took interest in 
these mitotic regulators and a number of cytoskeletal associated genes (table 1). To 
investigate the role of these genes in cancer thermosensitivity we utilised the cancer 
genomics open platforms cBioPortal and Xenabrowser (Goldman et al., 2020; Cerami et al., 
2012). We used these platforms to manipulate cancer genomic data sets in order to explore 
the expression of these genes in cancer and normal tissues. It is predicted that this analysis 
may elucidate potential molecular determinants of cancer specific sensitivity to HT. 
Elucidation of these mechanisms may aid in the design of adjunctive therapeutic cancer 
specific regimens and is thus of clinical importance.  
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2. Materials and Methods 
2.1. Materials 
All custom oligo-nucleotide primers and cell culture media were sourced from ThermoFisher 
(Invitrogen). 
All PCR kits and molecular biology reagents were sourced from New England Bio labs. 
Transfections carried out with Genejuice (Merck) transfection reagent. 
 
Table 2. Oligo-nucleotide sequences used to form poly-linker insertion and primers used for 
NEB HiFi cloning. 
Oligo name Direction Sequence 5' to 3' Tm(°C) 








































All PCR reactions carried out were done so under these conditions outlined in tables 3 and 4 
with amplification verification carried out through gel electrophoresis. 
 
Table 3. PCR cycling parameters (Touchdown) 
Step Temperature (oC) Time (s) 
Phase I (10 cycles)  
Initial denaturation 98 30 
Denaturation 98 10 
Anneal Tm + 10 30 
Elongate 72 60 (or more dependent on bp) 
Phase II (20 cycles)  
Denaturation 98 10 
Anneal Tm - 5 30 
Elongate 72 60 (or more dependent on bp) 












Component Volume (μl) 
Forward primer (10 mM) 2.5 
Reverse primer (10 mM) 2.5 
Phusion Hot-Start II Flex master mix 25 
DMSO 1.5 
DNA 1 ng 
dH2O X 
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2.2.2. Poly-linker synthesis  
Oligomer sequences outlined in table 2 were resuspended in TE buffer according to 
manufacturer’s specifications to produce a concentration of 1 μg/μl. 5 μl of each oligomer, 2.5 
μl 5x ligase buffer and 35 μl dH2O were mixed and incubated at 98 oC for 5 minutes in a PCR 
cycler. 
2.2.3. NEB HiFi  
PCR Amplified DNA was first treated with DpnI restriction enzyme (as outlined in table 6) to 
degrade template DNA. PCR amplified fragments were added at specific pmol ratios 
calculated using the formula (weight in ng) x 1,000 / (base pairs x 650 daltons). For insertions 
of fragments below 250 bp, a 1:6 vector/insert ratio was used. 10 μl NEB HiFi master mix and 
dH2O was added to total 20 μl as outlined in table 5. Mixtures were incubated at 50oC for 15 
mins in a PCR cycler. 
 







2.2.4. Restriction digests 
All enzymes and buffers were supplied by NEB labs. Digests were set up dependent on 
desired enzymes. Constituents were set up and mixed as outlined in table 6 and incubated at 
37 oC for one hour. Restriction enzymes used for screening, ligations and template 
degradation were: AgeI, NotI, PmeI, BamHI, SpeI, MluI, NruI, MfeI, DpnI. 
 
 
Table 6. Restriction enzyme digestion reaction constituents 




Triple digest  
DNA 2 2 2 
DNA ratio Vector/Insert 1:2 vol 
Total fragments 0.12/0.23 pmol X 
NEB HiFI master 
mix... 
 10 µl 
Water…  Up to 20 µl 
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Enzyme 1 1 1 1 
Enzyme 2 - 1 1 
Enzyme 3 - - 1 
Cutsmart 10x 2 2 2 
dH2O 15 14 13 
 
2.2.5. Ligations 
Table 7. Ligation reaction components. All ligation reactions were incubated at 4 oC for 24 
hours. Ligase and ligase buffer sourced from NEB labs. 
Ligation 1 (μl) 2 (μl) 3 (μl) 4 (μl) 
Recipient 1 1 1 1 
Donor 2 3 4 - 
10x T4 buffer 1 1 1 1 
T4 ligase 1 1 1 1 
dH20 5 4 3 7 
 
2.2.6.  DNA purification 
All Purification of PCR products was carried out using Purelink PCR purification kit 
(ThermoFisher). Manufacturers specifications were followed, expect for the case of 
elution, in which 30 µl elution buffer was used in order to generate a more 
concentrated sample. Briefly, 50 µl binding buffer was added to mixture and was 
loaded into the purification columns and centrifuged at >12,000 g for one minute. 
Elutant was then discarded and 600 µl wash buffer was added, before another three 
minutes of centrifugation at the same speed. Elutant was again discarded and 30 µl 
pre-warmed elution buffer was added to column and centrifuged at 12,000 g for two 
minutes. DNA concentration was measured using a Nano-drop instrument. 
2.2.7. Mini preps  
Mini preps were carried out with a ThermoFisher Scientific #K0502 kit according to 
manufacturer’s specifications. Briefly, three ml of LB broth was inoculated with a single 
bacterial colony using a pipette tip. Cultures were then incubated shaking at 37 oC for 24 
hours. The resultant cultures were then centrifuged at 12,000 G for two minutes, supernatant 
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removed, and cell pellet resuspended in 250 μl resuspension buffer (Including RNAase A). 
250 μl Lysis buffer was then added and incubated at RT for five minutes. 350 μl precipitation 
buffer was then added and mixed until homogenous before the mixture was centrifuged for 10 
minutes at 12,000 G, the supernatant was then further centrifuged in a spin column at the 
same G for one minute. The flow through was then discarded, and 700 μl wash buffer was 
added columns then centrifuged for one minute at 12,000 G, flow through discarded and spun 
again for a further minute. Spin columns then put into a elution tube, 30 µl of TE buffer added 
to column and spun at 12,000 G for one minute before DNA concentration was determined 
using a NanoDrop Instrument.  
2.2.8. Maxi preps 
Maxi preps were carried out with a ThermoFisher PureLink kit with modifications the 
manufacturer’s protocols as follows. A three ml miniprep starter culture was used to inoculate 
200 ml of LB and was incubated at 37 oC shaking for 30 hours. This mixture was then split 
evenly, to within 0.01 gram, between two Nalgene PPCO 250 ml centrifuge containers and 
span at 4,000 G for 10 minutes at four degrees Celsius. Supernatant was then removed, and 
pellet resuspended in 20 ml resuspension buffer. 20 ml lysis buffer was then added and 
mixture incubated for five minutes at RT. 20 ml precipitation buffer was added and then 
centrifuged at 4,000 G for one hour at RT. Supernatant was then added to equilibrated column 
and left to drain for 20 minutes. 60 ml wash buffer then added to the column and left to drain 
for 30 minutes. Columns then placed in falcon tubes and 15 ml elution buffer added to columns 
and allowed to drain into falcons. 10.5 ml IPA was then added to elution tube and mixed. 
Falcons then centrifuged at 4000g for one hour 30 minutes at 4 oC. Supernatant then removed, 
and pellet resuspended in five ml 70% ethanol. Mixture was then centrifuged again for 15 
minutes at 4,000 G at four degrees Celsius. The supernatant then removed and pellet allowed 
to air dry before being resuspended in 200 μl TE buffer and DNA quantified using a NanoDrop 
instrument. 
2.2.9. Electrophoresis  
All gel electrophoresis was carried out using a 0.5% w/v agarose, TBE (Tris/borate/EDTA) 
buffer gel with 1:20,000 SYBR safe stain (ThermoFisher) added for band visualisation. Gels 
were ran for one hour at 100 V using TBE as running buffer. 10x Sigma OG loading buffer 
was loaded with samples and seven μl of 1 Kb+ DNA fast ladder (ThermoFisher) used for 
band quantification.  
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2.2.10. Cell culture 
RPMI/Glutamax 1640 was used for all cell lines with 10,000 UI/ml and 10,000 μg/ml 
Penicillin/streptomycin added. For MCF-7 and Melan-A media 50 ml foetal calf serum (FCS) 
was added to each bottle (10%). For B16F10, 25 ml (5%) was added. Melan-A media also 
included 200 μM TPA. 
2.2.11. Cell passage 
Media was aspirated off before the cells were washed with two ml trypsin (Gibco). This trypsin 
was then aspirated and one ml fresh trypsin added and cells incubated at 37oC for five minutes 
to detach cells. Nine ml (complete as described) media was added to the flask and pipetted 
up and down to help detach cells. This trypsin/cell mixture was then added to a flask with 
desired ratio to fresh media. For MCF-7 cells this ratio was 1:5 trypsinate/media respectively.  
2.2.12. Cell counting 
Media was aspirated off before the cells were washed with two ml trypsin (Gibco). This trypsin 
was then aspirated and one ml fresh trypsin added and cell incubated for five minutes at 37oC. 
Once cells had visibly detached, nine ml media was added to the cells and pipetted up and 
down to detach cells. 200 μl of the suspended cells were then added to a haemocytometer. 
Cells/ml were calculated by counting the number of cells in one large square, five times, and 
producing an average cell count per large square. The resultant value x104 then produced our 
cell/ml value.  
2.2.13. Transfections 
All transfections were carried out with Genejuice (Merck) transfection reagent. Cells were 
seeded into 6-well plates at appropriate count (240,000 per well for MCF-7s). 24 hours later 
three μl Genejuice reagent and 100 μl Optimem reduced serum media were mixed and 
incubated at RT for five minutes. Varying quantities of DNA were then added to this mixture 
(as outlined in table 8) in order to find optimal molar ratio of PiggyBac and transposase 
plasmids (hybase) and incubated at RT for 20 minutes. Cell media was then replaced before 
transfection mixture was added dropwise to cells. 24 hours after cells were then split into 10 
cm dishes. After a further 24 hours the appropriate antibiotic selection media was added to 
the dishes. Transfections were validated through confocal microscopy.  
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Table 8. Transfection plasmid ratios  
Well Plasmid 1 (ul) 
PiggyBac-
Construct 
Plasmid 2 (ul) 
Transposase 
(Hybase) 
1 0 0 
2 2 0 
3 2 0.4 
4 1 1 
 
2.2.14. Transformations 
Five ng plasmid DNA was mixed with 50 μl dH5α chemically competent E. coli (ThermoFisher), 
cells were then incubated on ice for 30 minutes. The cells were then heatshocked for 30 
seconds at 42oC, 950 μl of pre-warmed SOC media was added and then incubated at 37oC 
for one hour. The cells were then spread onto LB agar plates containing appropriate antibiotic 
(100 μg/ml ampicillin or 50 μg/ml kanamycin). 
2.2.15. cBioPortal and XenaBrowser 
Analysis was carried out using the open source cancer genomics platform cBioPortal 
(https://www.cbioportal.org/). Genes outlined in table 1 were queried against TCGA Pan 
Cancer Studies consisting of 10967 samples from 32 studies. Genes were sorted into three 
catagories, mitotic regulators (KIF11, STAG2, NEK2, CHUK, KPNA4, CENPF, NCAPG), 
cytoskeletal associated genes (CFL1, CFL2, DSTN, RAPH1, EVL), and T-complex protein 
ring genes (TCP1, CCT2, CCT3, CCT4, CCT5, CCT6A, CCT6B, CCT7, CCT8 ). Each 
category was queried and data analysed independently. For cancer types summary both copy 
number alterations and mutations tabs were checked. Genes were queried independently for 
expression analysis between cancer types. For expression cancer specific analysis alteration 
data was sorted by median. For comparing transcript data the TCGA Pan Cancer Studies 
aforementioned were loaded into Xenabrowser (https://xenabrowser.net/) and compared with 
normal tissue expression data through the TCGA TARGET GTEx platform 
(https://gtexportal.org/home/). Each gene was queried individually in this manner with 
comparisons drawn between metastatic, primary tumour, normal tissue and solid tissue 
normal samples. 
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2.2.16. Confocal imaging and cell counting 
Cells were seeded at a density of 50,000 per well in 15 mm diameter 24-well glass bottom 
imaging plates. Four channels were used during acquisition, excitation and emission 
wavelengths are listed in table 9. Time intervals used during acquisition varied between 
experiments. Briefly, for MCF-7 37oC and 41oC runs data was collected in five minutes time 
intervals and all other imaging was done using 15-minute time points. All images were 
collected as seven slice Z stacks and maximum intensity projects generated post acquisition. 
33 oC treated lines were imaged at 0.8 zoom and all others at one. Cells in each field of view 
were counted manually using the Fiji cell counting tool. Percentage change in cell counts were 
calculated using the following equation where B = cell count at the beginning of treatment and 
E = cell count at the end of treatment. E/B x 100.  
 




All statistics were performed using GraphPad Prism version 8.4.3 (471) for Windows, 
GraphPad Software, San Diego, California USA, www.graphpad.com. Transcriptomic data 
analysed with One-way ANOVA followed by Dunnett’s multiple comparisons test. Cell 
tracking comparison done through students t-test with normality tested D'Agostino-Pearson 
test. Standard deviation listed alongside mean values. All data tested to significance level of 







Fluorophore  Excitation wavelength (λ) 
(nm) 
 
Emission wavelength (λ) 
(nm) 
 
mCherry 561 637 
mVenus 514 554 
CFP 458 521 
iRFP670 643 670 
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3. Results 
3.1. Biosensor construction 
3.1.1. PiggyBac vector multiple cloning site poly-linker insertion 
The PiggyBac transposase system can effectively and stably integrate multiple construct 
copies into cells without affecting genome integrity. We set out to utilise the system. The 
current PiggyBac plasmid available to us lacked multiple unique restriction sites. We thus 
modified our vector through the insertion of a custom multiple cloning site oligonucleotide to 
facilitate the generation of polycistronic biosensors from multiple construct copies. We built 
the linker to include multiple unique restriction enzyme cleavage sites (see fig 9A).Our poly-
linker was constructed with AgeI and NotI compatible sticky ends for ligation with our PiggyBac 
vector. We prepared mini-prep cultures transformed with our novel vector and screened the 
cultures using the restriction enzymes Mlul and BamHI. One of six mini prep cultures showed 
the predicted bands of ~5656 and ~1775 indicating successful ligation (fig. 9B). Figure 9C 
displays the resultant novel PiggyBac vector with multiple cloning site insert ready to accept 
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Figure 9. PiggyBac vector multiple cloning site insertion. A) Schematic of custom double 
stranded oligonucleotide polylinker sequence with restriction sites and cohesive ends marked. 
B) Gel electrophoresis of poly linker inserted vector Mlul and BamHI digestion products. One 
mini-prep displaying banding pattern of ~5656 and ~1775 confirming successful insertion. C) 
plasmid map of PiggyBac vector displaying inserted multiple cloning site. 
3.1.2. H1-Fucci(CA) PiggyBac vector insertion 
Fucci(CA) is a cell cycle biosensor with triple colour G1, S and G2 phase discrimination 
(Sakaue-Sawano et al., 2017). A modified polycistronic Fucci(CA), which includes the H1.0 
histone nuclear marker linked to cerulean fluorescent protein (CFP) has previously been 
constructed in the Mort lab (fig. 10A). To facilitate stable transfection, this construct was 
inserted into our previously modified PiggyBac vector. This was done via cutting the construct 
from the vector in which it was housed using MfeI and PmeI restriction enzymes leaving us 
with the linear construct ready for PiggyBac insertion. To screen for successful insertion, the 
plasmid was transformed and mini-prepped and triple digested with BamHI, NotI and Mlul 
restriction enzymes. Figure 10B shows the gel electrophoresis banding pattern confirming 
successful insertion. Our resultant stable expression vector housing the novel cell cycle and 




Figure 10. H1-Fucci(CA) PiggyBac vector insertion. A) Schematic of H1-Fucci(CA) 
biosensor displaying restriction sites used for vector insertion and self-cleaving P2A and T2A 
sequences B) BamHI, NotI and Mlul plasmid digestion agarose gel electrophoresis post-
cloning displaying expected banding pattern confirming successful insertion. C) Plasmid map 
of Pb-H1-Fucci(CA). 
3.1.3. Apoptosis Biosensor Design 
Apoptosis is indicated to be a prevalent form of cell death in HT. We therefore set out to extend 
our H1-Fucci(CA) biosensor by incorporating an apoptosis reporter. Nicholls and colleagues 
(2011) developed a dark-to-bright GFP apoptosis biosensor. The reporter functions through 
the linkage of a caspase-7 cleavable recognition site and hydrophobic quenching peptide at 
the C-terminus of GFP. This peptide quenches GFP fluorescence through disrupting proper 
chromophore maturation. Once apoptotic caspase cascade is initiated the quenching peptide 
is cleaved by caspase-7 and GFP is allowed to mature and fluoresce resulting in real time 
apoptosis monitoring. Our H1-Fucci(CA) biosensor consists of fluorochromes CFP, mCherry, 
and mVenus. Thus, to facilitate extension of our biosensor and avoid emission and excitation 
spectral overlap, we set out to utilise the far-red bacterial phytochrome iRFP670 for our 
apoptosis sensor. We linked this quenching peptide to iRFP670 in order to investigate whether 




















































this would adequately disrupt fluorescence. We used NEBuilder HiFi DNA assembly cloning 
to insert the quenching peptide at the C-terminus of iRFP670. Primers were designed to 
amplify the vector and insert with homologous regions to facilitate the HiFi assembly reaction 
(fig. 11A). Following construction, the vector was transformed, mini-prepped and screened 
through BamHI digestion. Both our insert and vector contain a single BamHI site (fig. 11C). 
Agarose gel electrophoresis confirmed successful insertion in all five mini-preps displaying 




Figure 11. iRFP670 apoptosis biosensor construction. A) PCR amplified linearised 
iRFP670 vector and quenching peptide insert with extended homologous ends to facilitate 
HiFi assembly. B) BamHI plasmid digestion agarose gel electrophoresis post-cloning 
displaying expected banding pattern of 4010 and 1052 bp confirming successful insertion. C) 






































3.2. Confocal microscopy biosensor validations 
3.2.1. MCF-7 H1-Fucci(CA) generation and construct validation  
HT is known to be particularly effective in treating breast cancer (Zagar et al., 2010). We 
therefore set out to use the breast cancer cell line MCF-7 as a model system to investigate 
thermosensitivity. To determine whether our PiggyBac-H1-Fucci(CA) vector (fig. 10C) 
functioned as expected we transfected MCF-7 cells with this vector. When imaged, the 
resultant cells produced stable nuclear (fig. 12D) and phase specific fluorescence (fig. 12B-
C), thus validating the expression of our probes and efficiency of our PiggyBac vector system, 
as well as providing a cellular tool for subsequent cell cycle thermosensitivity investigation. 
 
Figure 12. MCF-7 H1-Fucci(CA) (A) Brightfield representation of MCF-7 (B) Red channel 
displaying Cdt-mCherry probe (C) Green channel displaying Geminin-mVenus probe (D) Blue 
channel displaying the histone marker H1-CFP. Scale bar 50 µm. 
3.2.2. Caspase cleavable quenching peptide fails to disrupt iRFP670 
fluorescence 
To investigate iRFP670 dark to bright apoptosis biosensor suitability we transiently transfected 
MCF-7 cells with our iRFP670-Quenching peptide construct (fig. 11C). In addition, we 
transfected MCF-7 cells with a iRFP670 construct which lacked the quenching peptide in 
parallel as a negative control. Confocal microscopy indicated the quenching peptide was 
insufficient in disrupting fluorescence through observable fluorescence in iRFP670 quenching 
peptide transfected cells (fig. 13A). Thus, the peptide’s quenching capacity likely specifically 
impacts GFP chromophore structure.  
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Figure 13. MCF-7 expressing iRFP670-quencher and iRFP670 control A) MCF-7 
expressing iRFP670-quencher construct showing fluorescence indicating inefficient 
quenching. B) MCF-7 negative control expressing unmodified iRFP670. Scale bar 50 µm. 
3.3. Time lapse confocal microscopy  
3.3.1. MCF-7 41 oC incubation leads to reduced proliferation, endoreplication, 
and cell death via mitotic catastrophe 
Breast cancer is a particular malignancy that is known to respond to HT (Zagar et al., 2010). 
We therefore set out to investigate the impact of a range of temperatures on the growth and 
cell cycle phase dynamics of the breast cancer cell line MCF-7. It was intended that we would 
investigate thermosensitivity by utilising our previously constructed biosensor (fig. 10C) and 
novel MCF-7-H1-Fucci(CA) cell line (Fig. 12). We were unfortunately limited due to the forced 
closing of our lab during the coronavirus outbreak. Due to this reduced lab time we were 
unable to expand individual clones of our MCF-7-H1-Fucci(CA) cell line. Additionally, it was 
intended that we would transfect a immortalised breast epithelial cell line with our PiggyBac-
H1-Fucci(CA) vector (fig. 10C) to act as a normal tissue control for investigating cancer 




Figure 14 MCF-7 cells decrease in plate number when incubated at 41 oC. Cells were 
incubated for 48 hours at 33 oC, 37 oC and 41 oC and imaged. Cell count was quantified by 
manually counting cells at T=0 and T=48 hours. Percentage change in cell count over time 
was calculated using the following equation, where B = cell count at the beginning of treatment 
and E = cell count at the end of treatment. E/B x 100 (A-C) Imaging of MCF-7 at varying 
temperatures including cell counting overlay (D) Percentage change in cell count between 
zero and 48 hours displaying an increase of 164% at 33oC, 245% at 37 oC and a decrease of 
19% at 41 oC. Scale bar 50 µm. 
As an alternative we utilised a previously constructed MCF-7-Fucci2a cell line for 
thermosensitivity confocal imaging. Fucci2a functions similarly to Fucci(CA) although is unable 
to sharply discriminate S phase (Mort et al., 2014b). Cells were plated and incubated at either 
33 oC, 37 oC or 41 oC for 48 hours whilst live time-lapse confocal microscopy was 
simultaneously carried out. For an initial outlook on the impact of these different temperatures 
on the proliferation of MCF-7 we measured cell count at T=0 and T=48 hours by using the 
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ImageJ cell counting tool (fig. 14 A-C). As expected, the 37 oC treatment displayed the largest 
increase in cell count, showing a 245% increase in cell count at T=48 relative to T=0 (fig. 14D). 
An increase was also observed at 33 oC, with cells showing a percentage change increase of 
164% (fig. 14D). These data confirm cells grown at 33 oC demonstrate a reduced replicative 
capacity when compared with 37 oC incubation. In contrast, the cells treated at 41 oC showed 
a reduction in cell count of 19%. Thus, the hyperthermic range temperature of 41 oC retards 
cell viability of MCF-7. We next looked to investigate dynamic cell cycle phase alterations 
between temperature treatments. 
 
Figure 15. MCF-7 Fucci2a full cell cycle montages displaying phase specific 
fluorescence (A) Brightfield, red, green and merge montages of full cell cycle from mitosis to 
mitosis at one hour time points. (B) Merge channel montage displaying five minute time point 
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To demonstrate the cell cycle phase reporting capacity of our MCF-7-Fucci2a cell line we have 
constructed an individual time step montage of a full cell cycle at 37 oC. Figure 15A shows a 
full cell cycle at 1-hour time points and 15B displays individual 5-minute time points of MCF-7 
cycling. Both display mCherry (red) G1 fluorescence, mVenus (green) S/G2/M fluorescence, 





Figure 16. Incubating MCF-7 cells for 48 hours at 41 oC stalls leads to G1 stalling. MCF-
7 Fucci2a total cell cycle phases compared over time between temperature treatments. Cell 
cycle phases were tallied at T=0 and T=48 hours (A-C) Merge channel confocal imaging of 
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due to imaging acquired at 0.8 zoom, for further details in methods section (D) Cell cycle 
phases as percentages of total fluorescent cells at both time points showing all cells in 41 oC 
treatment stall in G1 after 48 hours. Scale bar 50 µm. 
In order to investigate cell cycle phase alterations between temperatures, we utilised a similar 
pipeline to our cell count analysis (fig. 14). Cells were plated, incubated at either 33 oC, 37 oC 
or 41 oC and imaged for 48 hours. The ImageJ cell counting tool was then used to quantify 
the total percentage of cells in a given phase at T=0 and T=48 hours. Figure 16A-C displays 
confocal Fucci2a imaging at T=0 and T=48 hours for each temperature treatment. We then 
quantified the total cells in a given phase and plotted as a percentage of total cells (fig. 16D). 
We observed slight differences in cell cycle phase percentages at T=0, although this is to be 
expected for homogenous asynchronous cell culture. After 48 hours the 33 oC and 37 oC 
treatments displayed slight changes in cell cycle phase percentages relative to T=0 (Fig. 16D). 
Conversely, at 41 oC a striking difference was observed, with all cells stalling in G1. We next 
set out to investigate differences in MCF-7 cell cycle phase duration between temperature 
treatments. 
 
To determine whether G1 or G2/M phase duration is impacted by temperature we tracked the 
intensity of the cell cycle phase specific mCherry and mVenus probes over full individual cell 
cycles. 10 full cell cycles for each treatment were tracked using a cell tracking ImageJ package 
developed in the Mort lab. This automated package measures the normalised integrated 
intensity of each probe during a full cell cycle. By tracking full cell cycles in this way, we were 
able to quantify the duration of G1 and G2/M phases by monitoring the rise and fall of the 
individual probes. Figure 17A and B both represent the tracking of one full cell cycle at 37 oC. 
This tracking allowed us to quantify G1 and G2/M phases by measuring the lengths of the 
respective peaks. In line with our previous analysis of counting cells  over time (fig. 14), we 
observed increased G1 and G2/M phase lengths in cells treated at 33 oC compared with 37 
oC (fig. 17C). The mean G1 and G2/M phase times at 33 oC were 1095 ± 269 and 1245 ± 237 
minutes respectively (n = 10 mitoses for each treatment). Both of these times were significantly 
longer than the cells treated at 37 oC (t-test P < 0.0001), which showed a duration of 642.5 ± 




Figure 17. MCF-7 cell cycle phase time tracking (A-B) Relative intensity plots showing 
mCherry and mVenus peaks. Each plot represents individual MCF-7-Fucci2a cells incubated 
at 37 oC. Each figure represents tracking of one full cell cycle. Tracking multiple cells in this 
way allows for estimation of G1 and S/G2/M phases. (C) Quantification of cell cycle phase 
lengths between temperature treatments. Incubating cells at 33 oC resulted in a statistically 
significant increase in G1 and S/G2/M phase lengths relative to 37 oC (**t-test P < 0.0001, 
normality tested using D'Agostino-Pearson test). 41oC treatment was unable to be analysed 
in this way due to the lack of observable full cell cycles (N.C. = Not calculated), Please refer 
to figure 18 for further details.  
We were unable to track cells incubated at 41 oC in this way due to the lack observable full 
cell cycles. When tracking these cells however, we observed a number of abnormal events. 
Due to the observation of reduced cell count over 48 hours (Fig. 14), we assumed the 
occurrence of cell death in our 41 oC treatment. Indeed, ~10 cellular death events (Fig. 18C) 
were observed at 41 oC. Interestingly, each of these occurrences of cell death occurred during 
mitosis. Figure 18A displays a montage of MCF-7 full cell cycle at 37 oC with focusing on 






Figure 18. Incubating MCF-7 cells at 41 oC increases endoreplication and cell death via 
mitotic catastrophe. Cells were incubated at 33 oC, 37 oC or 41 oC and simultaneously 
imaged for 48 hours. Montage time steps are indicated in figure (A) Montage displaying full 
MCF-7 cell cycle incubated at 37 oC with focusing on mitosis. (B) Montages displaying mitotic 
catastrophe and endoreplication events in cells incubated at 41 oC. In mitotic catastrophe, 
nuclear envelope breakdown occurs in similar manner to mitosis in 37 oC, followed by 
observable cell death and apparent membrane blebbing after ~300 minutes (12th time point). 
Endoreplication event is displayed showing cells transition from G2 back to G1 (without 
undergoing mitosis) in a duration of ~250 minutes (5 time points). (C) Quantification of mitosis, 
cell death, and endoreplication events in 33 oC, 37 oC and 41 oC treatments. 33 oC and 37 oC 































catastrophe events. The 41 oC incubated cells displayed 8 mitoses, 15 endoreplication events 
and 10 mitotic catastrophe events.  
 
-, as is displayed in the 3rd time point of the mitosis cell cycle montage displayed in figure 18A. 
In cell death at 41 oC, cells observably gained green fluorescence intensity and rounded 
marking mitosis, then stalled for ~250 minutes after nuclear envelope breakdown before 
observably shrivelling and dying (fig. 18B). This behaviour was similar in all occurrences of 
cell death at this temperature treatment. Thus, we propose the mechanism of cell death in 
MCF-7 at 41 oC may occur via mitotic catastrophe. However, further biochemical analysis 
should be carried out to verify our proposed cell death mechanism. A further interesting 
behaviour of endoreplication was observed in cells treated at 41 oC. Endoreplication is the 
duplication of genomic material in the absence of mitosis. We noted ~15 observable 
occurrences of cells entering G2, then cycling back into G1, as is displayed in figure 19B. We 
then tallied each of these events with mitoses in the 41 oC treatment and contrasted this with 
events at 33 oC and 37 oC (fig. 18C). The impact of this higher temperature treatment on 
aberrant cellular events and repressed proliferation is substantial. We therefore concluded 
that 41 oC treatment of MCF-7 induces both mitotic aberrations resulting in cell death and 
polyploidy through endoreplication. 
3.3.2. Melanocyte cell line Melan-A displays increased G1 phase duration at 33 
oC relative to the melanoma line B16F10 
Melanoma is further malignancy known to respond to HT. We therefore set out to investigate 
cell cycle thermosensitivity of the melanoma model cell line B16F10 and the immortalised 
melanocyte cell line Melan-A as a normal tissue control. Previous work carried out in the Mort 
lab led to the development of Fucci2a B16F10 and Melan-A lines. We utilised these lines to 
interrogate differences in thermosensitivity between melanoma and melanocytes. Due to the 
aforementioned limited lab time and technical issues with the department confocal, we were 



























Cells were plated, incubated at 33 oC, and imaged for 48 hours. Figure 19A displays both 
B16F10 and Melan-A at T=0 and T=48 hours. Firstly, we tallied the total cells in a given phase 
for each line at T=0 and T=48 hours using the ImageJ cell counting tool (Figure 19B). This 
analysis revealed no striking differences in total cell cycle percentages at either time point. 
We did observe a slightly higher percentage of cells in G1 at T=48 hours in each line (Fig 
19B). Although this effect is likely due to cells reaching confluency thus more cells arresting 
in G1 due to contact inhibition. 
 
To determine whether G1 or G2/M phase duration differed between cell lines we tracked 10 
full cell cycles for each line. We did this though utilising the aforementioned automated ImageJ 
cell tracking package developed in the Mort lab. This analysis produces normalised integrated 
intensities for both probes in each cell line tracked. Examples of these intensities are plotted 
and displayed in figure 20A-B. Figure 20A shows one full Melan-A cell cycle displaying a 
longer G1 (red) phase duration relative to both G2/M (green) and B16F10 G1 phases (Fig 
20B). We quantified G1 and G2/M phase durations of 10 cells for each line and found a 
significantly longer G1 phase in the Melan-A cell line. Melan-A G1 phase showed a duration 
of 885 ± 308 minutes when compared with the B16F10 line time of 565 ± 66 (Normality tested 
using D'Agostino-Pearson test, t test P = 0.0049)(fig. 20C). Determining whether this 
A B 
Figure 19. B16F10 and Melan-A display similar cell cycle phase totals at 33 oC. B16F10-
Fucci2a and Melan-A-Fucci2a total cell cycle phases compared over time between 
temperature treatments. Cell cycle phases were tallied at T=0 and T=48 hours. (A) Merge 
channel confocal imaging of different heat treatments displaying T=0 and T=48 hour time 
points. Cell cycle phases as percentages of total fluorescent cells at both time points. 
 49 




Figure 20. 33 oC B16F10 and Melan-A cell cycle phase tracking (A-B) Relative intensity 
plots displaying mCherry and mVenus peaks in one full Melan-A and B16F10 cell cycle 
respectively. Note observably longer G1 peak fluorescence relative to G2 in Melan-A plot 
when compared to B16F10. (C) Quantification of cell cycle phase lengths. Melan-A cells 
displayed a statistically significant increase in G1 phase length when compared with B16F10 
(n = 10, t-test P < 0.0049, normality tested using D'Agostino-Pearson test). **= Significant, ns 
= not significant. 
3.4. The cBio Cancer Genomics Portal 
3.4.1. Identification of cancer genetic alterations in gene groups of interest 
In order to investigate whether the genes outlined in table 1 conferred cancer specific 
thermosensitivity we utilised the open source cancer genomics platform cBioPortal (Cerami et 
al., 2012). We split our genes of interest into three groups; mitotic regulators, cytoskeletal 
associated proteins, and T complex protein ring (TRiC) proteins. In order to decipher whether 
these groups of genes were altered in cancer we queried each group of genes against 
collective TCGA PanCancer Atlas Studies. Analysing in this way queries each group of 
proteins against 32 studies each of which consisting of a different cancer type with a total 
sample count 10967. This analysis showed considerable alterations in each group across 
multiple cancers (Fig. 22). The Mitotic regulator group displayed a general high mutational 
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profile trend, most notably in uterine, bladder and melanoma malignancies (Fig 21A). This 
trend may be an artefact of general mutational burden, as opposed to functional driver 
mutations. Our cytoskeleton associated protein group displayed a similar trend, although 
notably uterine carcinosarcoma contained amplification or multiple alterations only (Fig 21B). 
The TRiC group displayed a trend of high gene amplifications across all cancers except uterine 
(Fig 21C). Moreover, given the complex’s key role in protein folding homeostasis, these 
amplifications led to us taking an interest in this group of proteins and carrying them forward 
for transcript expression investigation. We then moved to investigating differences in gene 
expression of these groups between cancer and normal tissues. 
3.4.2. Transcript-level expression analysis 
To determine whether these genes differed in expression between cancer and normal tissue 
we used the Xenabrowser platform to compare the expression of each individual gene of 
interest in all cancers against the Genotype-Tissue Expression (GTEx) project database 
(Goldman et al., 2020). GTEx consists of two main data of interest for our analysis, solid tissue 
normal, which is sampled near to tumour site, and normal tissue, which is taken from cancer 
free individuals. Using the Xenabrowser platform we compared the metastatic and solid 
tumour expression data of each our genes of interest against solid tissue normal and normal 
tissue data. Figure 22 lists two genes from each group which showed the most striking 
differences in expression. NEK2 displayed the most drastic increase in expression in cancer, 
with a normalised RNAseq count mean value of 8.1 +/- 2.1 and 8.6 +/- 1.2 for primary and 
metastatic tissues compared with 3.6 +/- 2.5 for normal tissue (P < 0.0001 One-way ANOVA 
with Dunnett’s Post-Hoc test)(fig. 22A1). NEK2 is a mitotic regulatory protein, which as 
aforementioned, displays a decrease in expression in response to hyperthermia (Amaya et 
al., 2014). The mitotic regulator NCAPG also displayed an increase in expression in cancer 
with respective primary and metastatic normalised RNAseq count means of 8.8 +/- 1.8 and 
9.7 +/- 1.1 compared with 5.2 +/- 2.0 for the normal control tissue (P < 0.0001 One-way 
ANOVA with Dunnett’s Post-Hoc test)(fig. 22A2). Thus, NCAPG may similarly play a role in 
cancer specific thermosensitivity. Of the cytoskeletal associated proteins we investigated, 
CFL1 and CFL2 showed the largest differences in expression in cancer. Both of which are 
actin modulating proteins. Interestingly these genes displayed significant contrasting 
differences in expression in cancer compared to normal tissue, with CFL1 showing an 
increase, and CFL2 a decrease (P < 0.0001 One-way ANOVA with Dunnett’s Post-Hoc 
test)(Fig. 22A1-2). Furthermore, in line our previous observation of gene amplifications (fig. 
21C), we observed a significant increase in expression in cancer in two subunits of the TriC 
 51 
complex (P < 0.0001 One-way ANOVA with Dunnett’s Post-Hoc test)(fig. 22 C1-2). These 
observation’s led us to explore alterations of these genes in specific cancer types. 
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Cytoskeleton Associated Proteins  





Figure 21 Cross cancer alteration summary of genetic changes in groups of genes 
hypothesised to confer thermosensitivity. All data obtained using cBioPortal comparative 
cancer genomics. Cohort: TCGA Pan Cancer Atlas studies (32 studies, 10967 samples) (A) 
Mitotic regulators (KIF11, STAG2, NEK2, CHUK, KPNA4, CENPF, NCAPG) displaying 
general tread of high mutational profiles. (B) Cytoskeleton associated proteins (CFL1, CFL2, 
DSTN, RAPH1, EVL) showing a general trend of gene amplifications (C) T-complex Protein 
Ring Complex proteins (TCP1, CCT2, CCT3, CCT4, CCT5, CCT5, CCT6A, CCT6B, CCT7, 
CCT8) showing a trend of gene amplifications across cancer types. 
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Figure 22. Tumour vs normal expression of genes hypothesised to confer thermosensitivity. 
TCGA Pan Cancer Atlas study cohort expression (32 studies, 10967 samples), compared with 
the Genotype-Tissue Expression (GTEx) data (19131 samples). (A1-A2) Mitotic regulatory 
proteins NEK2 and NCAPG displaying significant elevated expression when compared with 
normal tissue. NEK2 showing most drastic increase. (B1-B2) CFL1 and CFL2 actin dynamic 
stability displayed varied expression in cancer when with normal tissue. CFL1 displayed an 
increase relative to normal tissue, conversely, CFL2 displayed a decrease. (C1-C2) Both 
CCT6A and CCT2 displaying increased expression in cancer compared to normal tissue. All 
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comparisons of metastatic and primary tumour are significant compared to normal tissue One-
way ANOVA with Dunnett’s Post-Hoc test (P < 0.0001). 
 
3.4.3. Cancer specific alterations in genes of interest 
We then went back to the open source cancer genomics platform cBioPortal to investigate 
which specific cancer types contain genetic aberrations in our genes of interest. Each gene 
was queried individually against collective TCGA PanCancer Atlas Studies. This referenced 
each gene against 32 cancer subtypes from 10967 samples. In the mitotic regulatory proteins 
investigated NEK2 displayed high amplification and a high number of gene amplifications in 
breast cancer (Fig. 23). Breast cancer is known to respond to HT, and the treatment of such 
has been shown to reduce NEK2 expression (Amaya et al., 2014). Our observations support 
this previously highlighted importance of NEK2 in breast cancer, although further more 
detailed analysis is required to verify our findings.. The actin modulating genes CFL1 and 
CFL2 displayed no apparent correlation with cancer types (fig. 24).  The TRiC complex 
subunits CCT6A and CCT2 both showed highest expression in testicular germ cell cancer (fig. 
25). Both of which displaying high numbers of gains in copy number.  Whether this observation 
has any biological significance is inconclusive, although supports further investigation into the 





















Figure 23. Mitotic regulators NEK2 and NCAPG cancer specific mutations and copy number 
alterations. each spot-on figure represents a specific alteration. NEK2 showing high 






















Figure 24.  Cancer specific mutation and copy number alterations in cytoskeletal associated 




Figure 25. Cancer specific mutation and copy number alterations in T-complex protein ring 
complex proteins CCT6A and CCT2. Each spot-on figure represents a specific alteration. 





Interest in HT has undergone a resurgence in recent years due to innovations in methods of 
application and combination therapies (Datta et al., 2020). Despite this, the cellular and 
molecular rationale behind HT remains unclear. Fucci is a verified and established tool for the 
investigation of cell cycle dynamics in cancer (Prasedya et al., 2016; Yano et al., 2014). 
cBioportal is a powerful open source cancer genomics platform which allows for visualisation 
and analysis of large-scale genomics data sets (Cerami et al., 2012). These tools complement 
each other in developing the understanding of cancer, as is demonstrated in recent studies 
(Hastings et al., 2020; Markovsky et al., 2018). In this investigation, we have applied Fucci 
alongside cBioPortal based comparative genomics in order to shed light on the mechanisms 
underpinning HT’s efficacy in cancer treatment.  
4.1. Biosensor and cell line development 
4.1.1. A better multiple cloning site for polycistronic vector approaches 
The construction of polycistronic biosensors through the linkage of multiple components 
depends on multiple specific and novel restriction sites. Our transfection vector initially lacked 
such sites. In this study, we have constructed and inserted a novel multiple cloning site linker 
readily able to accept a variety of constructs through restriction cloning. Our vector with unique 
engineered multiple cloning site (fig. 9C) allows for the easy insertion of DNA consisting of a 
range of restriction sticky ends. This was demonstrated by the insertion of H1-Fucci(CA) via 
Mlul and BamHl restriction sites (fig. 10). The cloning site includes 6 unique restriction sites, 
making it a versatile and valuable tool for building polycistronic biosensors from multiple 
constructs. This is in line with previous work optimising and engineering vector cloning sites 
to allow for ease of restriction cloning (Staal et al., 2019, 2018).  
4.1.2. Developing a robust strategy for batch transformation of Fucci vectors 
with PiggyBac 
Transiently transfected genetic material is often lost during cell division. This approach is 
hence limited when using transgenetic biosensors to study the cell cycle. The PiggyBac 
transposase system is able to stably and efficiently genomically integrate constructs. We 
therefore set out to utilise this system to generate biosensor expressing cell lines to investigate 
HT in cancer. We have generated a PiggyBac vector housing the polycistronic cell cycle and 
histone biosensor H1-Fucci(CA)(fig. 10C). Moreover, we have demonstrated this systems 
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transfection ease and efficiency through the generation of a novel MCF-7 H1-Fucci(CA) 
expressing cell line (figure 12). This work supports previous reports of PiggyBac constituting 
an efficient vector in human cell genetic transfer (Wilson et al., 2007; Yusa et al., 2011). 
Fucci(CA) allows for the accurate discrimination of G1, S, G2/M cell cycle phases (Sakaue-
Sawano et al., 2017). Extending Fucci(CA) via the addition of the histone marker H1 linked 
with CFP expands spatial dynamic interrogation capability through facilitating the 
simultaneous tracking of chromatin organisation with cell cycle phases (Figure 12D). 
Furthermore, housing this construct in our PiggyBac vector system allows for future rapid and 
efficient H1-Fucci(CA) transfection in cell lines of interest, as demonstrated in Figure 12D. 
Unfortunately, in this study we were unable to utilise these novel tools for cancer cell 
thermosensitivity investigation. This is due to the coronavirus pandemic forcing the closing of 
our lab, as it did many others across the world (Vasiliadou, 2020). This limited lab time meant 
during this study we were unable to select MCF-7-H1-Fucci(CA) clones, or transfect further 
lines with our PiggyBac-H1-Fucci(CA) construct. For future cancer thermosensitivity 
investigation these tools will prove invaluable. A clear benefit of this biosensor is the inclusion 
of the nuclear marker H1. In our MCF-7 thermosensitivity imaging experiments we have shown 
the main mechanism of cell death in cells treated at 41 oC to occur via mitotic catastrophe 
(Figure19B). Simultaneous tracking of the H1 nuclear marker during these events will provide 
further insight into chromatin organisation during these events. (Wang et al., 2010) 
demonstrated the surface exposure of H1 in apoptotic cells and nuclear localised H1 in 
necrotic cells. Thus, tracking the localisation of H1 during cell death may provide insight as to 
whether apoptosis or necrosis follows mitotic catastrophe in MCF-7 HT response. 
4.1.3. Monitoring multiple cell cycle outcomes with a single vector 
The impact of HT on cancer cell cycling and cell fate is poorly understood. In particular the 
mechanism of cell death in response to HT is one of interest. Generating cellular tools able 
to report in real time on the cell cycle and cell fate will provide insight into these 
mechanisms. We therefore set out to generate a polycistronic biosensor able to report cell 
cycle phase dynamics and apoptosis. Nicholls and colleagues (2011) developed a 
genetically encoded GFP based apoptosis biosensor which functions as a dark to bright 
reporter. The sensor functions through the incorporation of a quenching peptide at the N-
terminus of GFP which disrupts proper chromophore maturation. Linking this peptide to GFP 
via a caspase-9 recognition motif results in a real-time dark to bright apoptotic biosensor. 
Identification of other fluorochromes able to function in this system will aid in the design of 
novel multi-colour biosensor imaging pipelines. iRFP670 is a bright and highly stable far-red 
fluorochrome which is well tolerated by live cells (Shcherbakova and Verkhusha, 2013). We 
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linked the aforementioned quenching peptide/caspase-9 recognition motif to the N terminus 
of iRFP670. Through MCF-7 transient transfection and subsequent time-lapse confocal 
imaging we found that the peptide is insufficient in quenching iRFP670 fluorescence (Fig. 
13A). Thus, iRFP670 is an unsuitable fluorochrome for a biosensor of this sort. Our findings 
indicate the quenching function of this peptide is unique to GFP and derivatives thereof. This 
supports a previous study which indicates that the peptide specifically disrupts GFP β-barrel 
formation and thus chromophore maturation (Nicholls and Hardy, 2013). iRFP670 is a 
bacterial phytochrome consisting of a bilin chromophore core, a drastically different structure 
and chemical configuration to GFP (Rockwell et al., 2006; Shcherbakova and Verkhusha, 
2013). We conclude these fluorochromes do not respond to quenching via linkage of this 
peptide. Moving forward in biosensor construction, replacing CFP in our H1 reporter (Fig. 
10C) with iRFP670 should function sufficiently as this reporter acts simply by localisation. 
This will allow for CFP, a derivative of GFP, to be linked to the quenching peptide and thus 
lead to a functional dark to bright apoptotic biosensor. A polycistronic biosensor capable of 
discriminating between G1, S and G2/M cell cycle phase state, in addition to, indicating 
apoptosis and chromatin organisation will be provide invaluable tool for thermosensitivity 
investigation. 
4.2. Thermosensitivity 
4.2.1. HT induces mitotic catastrophe and endoreplication in breast cancer 
Breast cancer is the second most common form of cancer among women and is estimated to 
affect at least 1 in 8 women in their lifetime (Rojas and Stucky, 2016). Despite breast cancer 
research being at the forefront of cancer biology for decades, the disease is often still fatal. In 
particular, hyper aggressive breast malignancies such as triple negative breast cancer carry 
with them extremely poor prognostic outcomes (Jitariu et al., 2017). Therefore, there is much 
effort in the oncology community to develop and harness novel therapeutic strategies to 
improve breast cancer patient outcome. HT is one such therapy of current high interest. HT 
has been shown to significantly reduce breast cancer growth and to improve the therapeutic 
ratio of conventional therapies (Zagar et al., 2010). Not surprisingly therefore, HT is commonly 
applied in clinic for breast cancer and is the subject of numerous ongoing clinical trials (Datta 
et al., 2020). Despite HT’s wide application, the mechanisms by which HT selectively inhibits 
tumour growth are poorly understood. In particular, the impact hyperthermia has on cell cycle 
phase dynamics in cancer remain unclear. Considering HT’s common combinatorial 
application alongside cell cycle phase specific drugs, elucidating the effects of HT on cell cycle 
dynamics in breast cancer may aid in the design of therapeutic regimens (Otto and Sicinski, 
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2017). In this study, we employed the breast cancer cell line MCF-7 as a model to investigate 
the effect of HT cell cycle phase dynamics. 
 
Through utilising the cell cycle biosensor Fucci2a and performing live time-lapse confocal 
microscopy we observed recurrent cell death in HT treated cells specifically at the point of 
mitosis. We propose this phenomenon to be mitotic catastrophe induced cell death. Mitotic 
catastrophe is a pre-stage of cell death which occurs preceding necrosis or apoptosis 
(Vakifahmetoglu et al., 2008). This finding is consistent with previous reports indicating HT 
induces mitotic catastrophe in both breast and lung cancer cells (Giovinazzi et al., 2013; 
Pawlik et al., 2013a). It should be noted that mitotic catastrophe is also induced by microtubule 
hyper-polymerising and depolymerising drugs, such as taxanes and Vinca alkaloids 
respectively (Castedo et al., 2004). The induction of mitotic catastrophe by microtubule 
aberration coupled with HT’s induction of mitotic catastrophe support further investigation into  
cancer specific microtubule molecular alterations as a potential  mechanism by which cancer 
cells are susceptible to HT. This will be further discussed in section 4.2.3. 
 
Furthermore, through our imaging pipeline we found HT induces endoreplication and G1 
phase stalling in MCF-7 cells. Endoreplication is defined as the replication of genetic material 
in the absence of mitosis resulting in polyploidy (Lee et al., 2009). Endoreplication is essential 
for normal developmental and physiological processes (Fox and Duronio, 2013). An example 
of such is megakaryocyte endoreplication (Sher et al., 2013). Megakaryocytes are rare cells 
which can undergo cellular enlargement and endoreplication which can amplify DNA up to 64-
fold in order to facilitate platelet biogenesis (Patel et al., 2005). A previous study has confirmed 
Fucci2 as a reliable indicator of endoreplication through observing Fucci2 probes in 
megakaryocyte endoreplication cycling (Sakaue-Sawano et al., 2011). Induction of 
endoreplication and polyploidy in cancer has been similarly observed in response to anti-
cancer drugs, the most prevalent and well documented of which being topoisomerase II 
inhibitors (Cortés and Pastor, 2003). Interestingly, HT has previously been shown to enhance 
the sensitivity of cancer cells to topoisomerase II targeting drugs, and has been indicated to 
cause nuclear protein aggregation at the sites of topoisomerase-II DNA interaction (Hirohashi 
et al., 1995; Kampinga, 1995)(Hirohashi et al., 1995). These reports suggest that an alteration 
in topoisomerase II function or downstream signalling is a potential causal mechanism for the 
increased endoreplication events in response to HT seen in figure 19B. Further investigation 
of this potential causal relationship may aid in the design of HT topoisomerase II inhibitor 
combinatorial regimens.  
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As aforementioned we were greatly limited for laboratory time in this study due to the 
coronavirus pandemic causing the closing of our department. This led to us being unable to 
perform many experiments which were initially planned. Immortalised cell lines are a powerful 
tool for studying and comparing neoplastic and normal cell physiology (Boehm and Hahn, 
2004). Moving forward, the generation of a Fucci immortalised mammary epithelial cell will be 
useful for thermosensitivity investigation. As previously stated, whether there are intrinsic 
cellular differences in sensitivity to HT between normal and cancer cells is unclear and 
somewhat controversial. The generation of a normal tissue Fucci control for HT treatment and 
subsequent imaging alongside MCF-7-Fucci2a may offer insight into this unanswered 
question. In addition, it will also be useful to examine triple negative breast cancer cells lines, 
such as BT549 or MDA-MB-231, for their responses to HT as triple negative breast cancer 
has a high therapeutic need. Furthermore, the precise mode of cell death following mitotic 
catastrophe remains unclear. Pawlik and colleagues (2013) indicated apoptosis to occur 
following mitotic catastrophe in lung cancer cells treated with HT. This prediction is based only 
on morphological characteristics however, thus, further investigation is required in order for a 
more definitive conclusion to be drawn. Whether HT induces apoptosis occurs via intrinsic, 
extrinsic, or endoplasmic pathways (as reviewed (Ahmed et al., 2015) remains unclear. To 
interrogate these pathways, the aforementioned dark to bright apoptosis biosensor may 
provide a useful tool. Given the sensor functions through reporting the catalytic activation of 
caspase-9, and thus intrinsic apoptosis activation, we propose the sensor may act similarly 
when replacing the recognition motif to report on the catalytic activation of an alternative 
pathway. By replacing the caspase-9 recognition motif with the extrinsic pathway specific 
caspase-8 recognition sequence, one may be able to generate apoptotic pathway specific 
real-time genetically encoded biosensors. Transfecting these sensors alongside Fucci2a in 
both normal tissue and MCF-7 cell lines may prove fruitful in uncovering cancer specific 
thermosensitive cell death mechanisms.  
 
We have demonstrated the induction of mitotic catastrophe, endoreplication, and G1 phase 
stalling in breast cancer cells in response to HT. These findings coincide with previous reports 
of mitotic catastrophe based cell death induction (Giovinazzi et al., 2013; Pawlik et al., 2013b). 
Moreover, to our knowledge we have illustrated for the first time the induction of 
endoreplication in breast cancer in response to HT alone. However, generating biological 
replicates for these experiments is required in order to solidify these findings. This work may 
guide the design of future themosensitivity investigation.  
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4.2.2. Melanoma 
Melanoma is a further malignancy of interest for HT treatment (Mantso et al., 2018). We 
therefore set out to interrogate the effect of temperature on melanocyte (Melan-A) and 
melanoma (B16F10) Fucci2a cell lines. We were unfortunately limited to analysing just 33 oC 
treatment however, due to the coronavirus pandemic reducing lab time and technical issues 
with the department’s confocal microscope. We had initially intended on investigating a range 
of temperatures, from 33 oC up to HT relevant temperature treatment. Our thermosensitivity 
imaging pipeline has demonstrated its effectiveness through analysing MCF-7 cells. Moving 
forward, investigating HT range temperature in both melanoma and normal tissue control lines 
may shed light on intrinsic cellular differences between cancer and normal cell 
thermosensitivity. We did observe significantly longer G1 phase durations in Melan-A 
compared with B16F10. Although whether this phenomenon is a function of temperature, or 
general differences in cell cycling between lines is yet to be resolved. Further experiments 
using a range of temperatures will shed light on this. 
4.2.3. NEK2 is a key player in HT and mitotic catastrophe? 
HT is currently the focus of many clinical trials in a range of cancers including ovarian, bladder, 
breast and neurological malignancies to name just a few (Cowan et al., 2017; Longo et al., 
2016; Mahmoudi et al., 2018; Mu et al., 2018). Currently the molecular determinants which 
sensitise cancer to HT are poorly understood. In addition, specific cancer type responses to 
HT are underexplored. Identification of the genetic changes and molecular pathways which 
confer HT response in cancer may facilitate the development of novel therapeutic strategy. 
Moreover, predicting which specific cancer subclasses may respond to HT could guide the 
design of future cancer thermosensitivity studies. In this study we utilised the bioinformatic 
open platforms cBioPortal and Xenabrowser to explore the genetic changes of three 
categories of genes in cancer which we have hypothesised to be involved cancer 
thermosensitivity (Goldman et al., 2020; Cerami et al., 2012). 
 
Amaya and colleagues (2014) demonstrated reduced expression of the mitotic regulators 
KIF11, STAG2, NEK2, CHUK, KPNA4, CENPF and NCAPG in HT treated breast cancer cells. 
Through cross referencing Pan Cancer Genome atlas studies with Genotype Tissue-
expression data we identified NEK2 as being highly differentially expressed in cancer. In 
particular, we found NEK2 displayed a striking number of gene amplifications in breast 
invasive carcinoma (fig. 22A1). It should be noted however that this observation lacks 
statistical investigation due to time constraints, so should be considered speculative. However, 
the observation is consistent with previous reports of NEK2 being over expressed in a variety 
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of cancers and in particular in breast cancer (Wang et al., 2011). NEK2 is an oncogenic 
multifunctional serine/threonine kinase which plays roles in cell cycle control, centrosome 
amplification, and microtubule stability (Fang and Zhang, 2016). There is currently high 
interest in targeting NEK2 as a therapeutic approach for breast cancer. Small molecular 
inhibitors have shown significant anti-cancer activity in vitro and in vivo murine xenograft 
models (Henise and Taunton, 2011, p.2; Kokuryo et al., 2007, p.2). The efficacy of NEK2 
inhibition combined with finding that HT acts to reduce the expression of NEK2 in breast 
cancer suggests HT’s anti breast cancer activity may function through impacting NEK2 
signalling. Moreover, NEK2 has been demonstrated to play an essential role in the integrity of 
centrosome structure and microtubule nucleation activity (Jeong et al., 2007). Aberrant 
centrosome structure and spindle formation is associated with high rates of mitotic catastrophe 
(Pihan, 2013). We propose high rates of mitotic catastrophe to occur in MCF-7 cells treated 
with hyperthermia (fig 19B). This observation alongside these reports indicate HT’s anti breast 
cancer activity may function via reducing NEK2 expression/activity, leading to disruption of 
centrosome integrity and thus mitotic catastrophe. In further support of NEK2 playing a key 
role in HT, the cancers we found to most highly express NEK2 (cervical, oesophageal, 
stomach and ovarian) are each known to respond well to HT (Franckena et al., 2009; Gori et 
al., 2005; Hulshof et al., 2009; Kaaij et al., 2017). Future directions should include investigating 
the mechanism of HT reduced NEK2 expression in cancer previously observed (Amaya et al., 
2014). NEK2 expression is complex, showing regulation at both the transcriptional and post-
transcriptional level (Hames and Fry, 2002). Chromatin immunoprecipitation and proteomic 
avenues of investigation may prove insightful in elucidating any effects HT has on NEK2 
transcriptional regulators or signalling pathways. Additionally, knockdown of NEK2 in breast 
cancer cells, using siRNA for example, and simultaneously treating these cells with HT may 
prove fruitful. A combinatorial effect of these perturbations may uncover further mechanistic 
insight into HT in breast cancer, in addition to, guiding the design of therapies. 
4.2.4. TRiC and testicular cancer  
Hyperthermia’s aberrant effects on microtubules are well established (Coss and Linnemans, 
1996). We therefore took interest in the microtubule regulatory TRiC complex. TRiC is a 
chaperone complex which mediates protein folding in the cytosol, most notably tubulin and 
actin, as is required for their proper folding (Dunn et al., 2001). We rationalised therefore that 
cancer genetic alterations in components of this complex in cancer may lead to increased 
thermosensitivity. Indeed, we found two subunits of this complex CCT6A and CCT2 to show 
increased expression when cross referencing Pan Cancer Genome atlas studies with 
Genotype Tissue-expression data (fig. 22C1-C2). When we referenced the expression of 
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CCT6A and CCT2 against specific cancers we found the highest expression of both genes in 
testicular germ cell cancer out of all 32 cancer types investigated (fig 23C1-C2). Almost all 
alterations of CCT6A and CCT2 being gene amplifications. These observations suggest TRiC 
components as being potentially upregulated in testicular cancer, however, further 
investigation is needed in order to verify this proposal. Interestingly, a recent study from Guest 
and colleagues (2015) identified CCT2 and TCP1 (another TRiC subunit) as being necessary 
for the survival of breast cancer cell line SUM-52. The study further found CCT2 and TCP1 to 
be determinants of overall survival in breast cancer patients. These data suggest TRiC 
complex components function as drivers in breast cancer. This supports further investigation 
into TRiC’s potential role in testicular cancer. Exploring potential correlation of components of 
TRiC with testicular cancer patient survival and in vitro RNAi knock down study represent 
potential avenues of investigation. Whether this complex contributes to cancer specific 
thermosensitivity remains inconclusive. 
4.3. Conclusion  
We here describe the cell fates of the model breast cancer cell line MCF-7 in response to HT. 
We have constructed a novel cell cycle and chromatin state biosensor transfection vector and 
demonstrated its functionality through the generation of the MCF-7 H1-Fucci(CA) cell line. 
Moreover, we have proposed potential molecular mechanisms responsible for cancer cell 
specific thermosensitivity through interrogating genomic alterations in cBioPortal. This work 
may guide further investigation into the thermosensitivity of cancer cell cycle dynamics, 
provide tools for cell cycle study, and has given insight into potential molecular determinants 
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